Member Announcements 2004

 

December 30, 2004

Chemokine Therapeutics Corp. Completes Initial Public Offering
VANCOUVER, Dec. 30 /PRNewswire-FirstCall/ — Chemokine Therapeutics Corp. (TSX:CTI), a biotechnology company developing drugs in the field of chemokines and cytokines, today announced its initial public offering, consisting of a new issue of 16,000,000 common shares priced at Cdn$1.00 per share, for gross proceeds of Cdn$16,000,000. Chemokine Therapeutics’ common shares are expected to trade on the Toronto Stock Exchange under the symbol “CTI” at market opening today.

 

December 24, 2004

Ondine Announces Toronto Stock Exchange Listing
VANCOUVER, Dec. 24 /CNW/ – Ondine Biopharma Corporation ( TSX-V:OBP, AIM: OBP) announced that the Company’s shares will begin trading on the TSX at the market open today and will concurrently delist from the TSX Venture Exchange. The trading symbol for Ondine’s shares will remain “OBP”.

 

December 23, 2004

Cardiome Completes Oxypurinol Trial Enrolment
Vancouver, Canada, December 23, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has completed patient enrolment in its Phase 2 congestive heart failure study, OPT-CHF. The placebo-controlled study investigates the impact of 24 weeks of daily oral dosing of oxypurinol (600 mg/day) on the clinical outcomes of an expected 405 heart failure patients. The last patient was enrolled on December 22, 2004.

 

December 22, 2004

Inex Pharmaceuticals Names Timothy M. Ruane as Senior Vice President, Corporate Development
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) is pleased to announce that it has appointed Timothy M. Ruane, a corporate executive with significant pharmaceutical and oncology drug development experience, to oversee the Company’s corporate development initiatives.

 

December 22, 2004

New study shows paclitaxel may benefit Alzheimer’s and Parkinson’s movement disorders
VANCOUVER, Dec. 22 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced that a preclinical study published in today’s early edition of the Proceedings of the National Academy of Sciences highlights the positive effects of PAXCEED(TM) on movement disorders commonly seen in diseases known as taupathies, such as Alzheimer’s and Parkinson’s.

 

December 21, 2004

ELIGARD ® Gains Approvals in 24 European Countries
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today its development partner, MediGene AG, together with marketing partner Yamanouchi, successfully completed the Mutual Recognition Procedure (MRP) and gained approvals in 24 of 26 countries throughout Europe for the Eligard ® one-month (7.5mg) and three-month (22.5mg) products. In accordance with MRP, each of the EU member states gained market approval in their respective countries using the approvals obtained for Eligard in Germany as a reference.

 

December 21, 2004

AVID System Receives US Patent
For Immediate Release December 21, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) MDX Medical Inc. (TSX.V: MDX) has received a new United States Patent, No. 6,826,313, for the AVID System. The patent, entitled “Method and Automated System for Creating Volumetric Data Sets”, covers a key aspect of the AVID software, which allows the AVID system to automatically orient the measured film data and resample the planned data at the exact coordinates. This is a significant advantage over competitors’ film registration mechanisms, resulting in improved accuracy and savings in time.

 

December 20, 2004

Cardiome’s Pivotal AF Study Achieves Primary Endpoint
Vancouver, Canada, and Deerfield, IL, USA, December 20th, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) and its co-development partner Fujisawa Healthcare, Inc. today announced results from their recently completed 416-patient atrial arrhythmia phase 3 clinical study, called ACT 1. The study showed that of the 237 patients with recent-onset atrial fibrillation (AF), 52% of those receiving an IV dose of RSD1235 converted to normal heart rhythm, as compared to 4% of placebo patients (p<.001).

 

December 20, 2004

Allon granted European patent for learning and memory compound
VANCOUVER, Dec. 20 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), the “Neuro Protection Company”, announced today that it has been granted a European patent for a new class of orally bioavailable drugs that have shown promise in the improvement of learning and/or memory.

 

December 20, 2004

Response Biomedical Signs Agency Agreement, Amends Proposed Financing
VANCOUVER, Dec. 20 /CNW/ – Response Biomedical Corp. (TSX-V: RBM), today announced it has signed an agency agreement with Haywood Securities Inc. relating to the proposed best efforts private placement announced November 15, 2004. Based on the level of interest received to date, the Company has increased the upper limit of the financing from $1.5 to $3.0 million. Up to 4,000,000 Units are to be placed at a price $0.75 per Unit, each Unit consisting of one common share and two non-transferable one-half of one common share purchase warrants.

 

December 17, 2004

Cardiome to hold conference call
Vancouver, Canada, December 17th, 2004 Cardiome Pharma Corp (NASDAQ: CRME, TSX: COM) today announced that it will hold a teleconference and webcast on Monday December 20th at 7am PST, 10am EST.

 

December 17, 2004

Dragon and Oriental Wave Extend the Share Purchase Agreement in Connection with the Proposed Acquisition
VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ – Dragon Pharmaceutical Inc.(OTC BB: DRUG; TSX: DDD; BBSE: DRP) announces that the Company and OrientalWave Holding Limited have agreed to extend the Share Purchase Agreement toFebruary 28, 2005 in connection with the proposed acquisition of OrientalWave.

 

December 16, 2004

Chromos enters into agreement with Pfizer to develop cell lines for production of recombinant proteins
BURNABY, BC, and SEATTLE, WA, Dec. 16 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that it has entered into a collaborative agreement with Pfizer Inc., to develop cell lines using the ACE (Artificial Chromosome Expression) System for production of Pfizer recombinant proteins.

 

December 15, 2004

FDA Approves Eligard(R) Six-Month Formulation For Prostate Cancer
VANCOUVER, Dec. 15 /PRNewswire-FirstCall/ — CANADA-QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) for Eligard(R) 45mg (leuprolide acetate for injectable suspension) six-month formulation, for the palliative treatment of advanced prostate cancer. Similar to the other Eligard products, this approval came in 10 months, well ahead of the standard 12-month review.

 

December 15, 2004

StemCell Technologies to distribute AllCells’ product line worldwide
StemCell Technologies, Inc. (Vancouver, BC) announced today that it will distribute the full product line of AllCells, LLC (Berkeley, CA) to the global life science research market. The agreement gives StemCell semi-exclusive distribution rights to North America and exclusive distribution rights in the rest of the world, excluding Japan and China.

December 15, 2004

MDX Medical: Product Launch and Corporate Update
For Immediate Release December 15, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) is pleased to report the successful launch of the AVID System at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Conference held recently in Atlanta, GA.

 

December 14, 2004

INEX Sets New Course for FDA Approval For MARQIBO
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today it is reducing its workforce and taking other measures that will extend its financial resources to allow the continued development of the Company’s lead anticancer drug MarqiboTM.

 

December 14, 2004

Abgenix Announces Proposed Private Offering of Convertible Senior Notes
FREMONT, Calif.–(BUSINESS WIRE)–Dec. 14, 2004–Abgenix, Inc. (Nasdaq:ABGX) today announced that it intends, subject to market and other conditions, to sell approximately $150 million principal amount of its Convertible Senior Notes due in 2011, through a private placement under Rule 144A of the Securities Act of 1933.

 

December 13, 2004

Ondine Biopharma and Henry Schein enter into strategic distribution agreement
VANCOUVER, Dec. 13 /CNW/ – Ondine Biopharma Corporation (TSX-V:OBP, AIM: OBP) (“Ondine”) announced today that a strategic agreement in which Henry Schein (Nasdaq: HSIC), the largest distributor of healthcare products and services to office-based practitioners in the combined North American and European markets, will become the exclusive distributor of dental products utilizing Ondine’s innovative, patented platform technology, PhotoDynamic Disinfection (PDD).

 

December 13, 2004

Allon files IND for approval of Alzheimer’s clinical trials
VANCOUVER, Dec. 13 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), the “Neuro Protection Company”, announced today it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the Company’s lead product AL-108 as a treatment for Alzheimer’s disease.

December 9, 2004

Inflazyme PDE4 Compound Commences Phase I Clinical Trials
RICHMOND, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced that its licensee, Helicon Therapeutics, Inc., of Farmingdale, NY, has commenced Phase I human clinical trials with an Inflazyme compound, IPL455,903 (otherwise known as HT-0712). IPL455,903 is being developed by Helicon as a potential new treatment for disorders of learning and memory.

 

December 9, 2004

Chromos announces publication of a landmark article describing its Artificial Chromosome Engineering System (ACE System) in Nucleic Acids Research
BURNABY, BC, Canada and Seattle, WA, USA: Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) today announced publication of a landmark paper on its unique proprietary technology, the ACE System, in Nucleic Acids Research. The article, entitled “A mammalian artificial chromosome engineering system (ACE System) applicable to biopharmaceutical protein production, transgenesis and gene-based cell therapy”, reports data related to generation and certain applications of the ACE System.

 

December 9, 2004

Red Herring Selects Kinexus Bioinformatics Corporation For Prestigious Red Herring Top 100 Innovators Award
VANCOUVER, Dec. 9 /CNW/ – Kinexus Bioinformatics Corporation, a Canadian proteomics company is pleased to announce that it has recently been selected as a Top 100 Innovator by Red Herring, the award winning Silicon Valley media company that covers technology, innovation, entrepreneurship and business. The award honors 100 international public and private companies that have made their mark with critical contributions in technologies, products and services and have demonstrated creativity and innovation in marketing, sales, financing, human relations and business strategies.

 

December 9, 2004

XILLIX Receives 2 U.S. Patents for Fluorescence Endoscopy Systems —Company Also Updates Status of PMA Supplement Review
Richmond, B.C. – Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that the U.S. Patent Office has granted to Xillix patent number 6,821,245B2 entitled “Compact Fluorescence Endoscopy Video System”. This patent covers innovations in Xillix’s latest product, the Onco- LIFEâ„¢ device, including the multi-mode light source, compact camera and color balance feature which enable Onco-LIFE to be used with different endoscopes. The U.S. Patent Office also issued a notice of allowance for an additional patent entitled “Fluorescence Endoscopy Video Systems with No Moving Parts in the Camera.”

 

December 8, 2004

Twinstrand Therapeutics appoints Robert Fildes and Jeanne Bertonis to Board of Directors
BURNABY, British Columbia, Canada December 8, 2004 – Twinstrand Therapeutics Inc., a clinical stage oncology company, today announced the appointment of Dr. Robert Fildes and Ms. Jeanne M. Bertonis as new independent Directors to the company’s Board. The Board has also elected Dr. Fildes as Twinstrand’s new Chair.

 

December 8, 2004

Ondine Biopharma Announce Changes to the Board of Directors
VANCOUVER, Dec. 8 /CNW/ – Ondine Biopharma Corporation (TSX-V:OBP, AIM: OBP) (“Ondine”) announced today that Mr. Pierre Leduc, a veteran of the medical device industry, has been appointed to the Company’s Board of Directors and will become a member of the Board’s Audit Committee.

 

December 8, 2004

MIGENIX Reports Second Quarter Fiscal Year 2005 Financial Results
VANCOUVER, BC and San Diego, CA, Dec. 8 /CNW/ – MIGENIX Inc. (TSX: MGI;OTC: MGIFF), a clinical-stage developer of drugs for infectious anddegenerative diseases, provides an update on its programs and activities andreports financial results for the three and six month periods ended October31, 2004:

 

December 7, 2004

Xenon Announces Appointment of Chief Financial Officer
VANCOUVER, Dec. 7 /CNW/ – Xenon Pharmaceuticals Inc., a drug discovery and development company, is pleased to announce today that it has appointed Vijay Sondhi as Chief Financial Officer.

 

December 6, 2004

ID Biomedical announces strategic alliances for U.S. marketing and distribution of Fluviral vaccine
VANCOUVER, Dec. 6 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it has signed long term marketing, distribution and minimum purchase agreements with three of the largest influenza vaccine wholesalers in the United States: Henry Schein, Inc.; AmerisourceBergen Corporation’s Specialty Group; and McKesson Corporation.

 

December 6, 2004

AnorMED announces early results hold promise for new stem cell mobilizer in allogeneic transplant for cancer patients
VANCOUVER, Dec. 6 /CNW/ – AnorMED Inc. (TSX:AOM) announces preliminary results on AMD3100, its lead drug candidate for stem cell transplantation, which support its potential use as a single agent to mobilize stem cells from healthy donors for allogeneic stem cell transplantation in cancer patients. This data was reported for the first time today at the 2004 American Society of Hematology conference (ASH) held in San Diego.

December 6, 2004

New test for transplant rejection on the horizon
Vancouver – Researchers at St. Paul’s Hospital and Vancouver General Hospital are developing a revolutionary new test to diagnose and facilitate treatment of organ rejection in transplant patients.

 

December 2, 2004

Cardiome Congestive Heart Failure Trial to Continue
Vancouver, Canada, December 2, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that its independent Data Safety Monitoring Board (DSMB) has recommended that the phase 2 clinical trial OPT-CHF should continue as planned. The randomized, placebo controlled OPT-CHF is evaluating oxypurinol as an add-on treatment for class III-IV Congestive Heart Failure. The recommendation was based on the second of three planned safety analyses of data from patients who have completed the 24 week trial and a review of safety data from all patients currently enrolled in the trial.

 

December 2, 2004

AnorMED receives FDA response to Special Protocol Assessment and initiates pivotal Phase III program for new stem cell transplant drug candidate
VANCOUVER, Dec. 2 /CNW/ – AnorMED Inc. (TSX:AOM) announced today that it has received a response from the U.S. Food and Drug Administration (FDA) regarding its Special Protocol Assessment (SPA) on the design for two pivotal Phase III clinical trials of AMD3100, a potential new stem cell mobilizing agent for stem cell transplantation in cancer patients. A SPA provides a forum for the FDA and a Company to reach agreement as to the design, execution, and analyses proposed for regulatory approval in protocols reviewed under this process.

 

December 2, 2004

Stressgen Completes Enrollment in HspE7 Internal Genital Warts Trial
SAN DIEGO, CA, Dec. 2 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announces that it has completed enrollment of 30 patients in the Phase II clinical trial of its lead product candidate, HspE7, to treat internal genital warts, a human papillomavirus (HPV)-related disease. Surgery remains the principal means of treatment for internal genital warts today.

 

December 2, 2004

Chromos and Ohio State University to present data at American Society of Hematology Meeting showing transfer of chromosome-based expression vehicle to
BURNABY, BC, Dec. 2 /CNW/ – Chromos Molecular Systems Inc. (“CHROMOS”; TSX: CHR) and its collaborator at The Ohio State University will present data from Chromos’ ACE System (Artificial Chromosome Expression System) at the 46th Annual Meeting of the American Society of Hematology in San Diego, CA. The data demonstrate transfer of the ACE into hematopoietic cells and stable maintenance of transgene expression. This development further demonstrates the unique advantages of the ACE System in pursuing commercial opportunities in gene therapy for ex vivo and cell therapy applications.

 

December 1, 2004

Forbes Medi-Tech’s Manufacturing Facility Expanded to 1500 Metric Tonnes
Vancouver, BC — Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ: FMTI) announced today that the expansion of its joint venture’s manufacturing facility in Pasadena, Texas is complete. The Phyto-Source, LP plant’s capacity has been successfully increased by 50% from 1000 metric tonnes annually to 1,500 metric tonnes in anticipation of increased demand for the Company’s cholesterol-lowering ingredients, Reducol(tm) and Phyto-S Sterols.

 

December 1, 2004

AnorMED evaluates new stem cell transplantation drug candidate as single agent in multiple myeloma patients and as combination regimen in patients wit
VANCOUVER, Dec. 1 /CNW/ – AnorMED Inc. (TSX:AOM) announced today the initiation of two new Phase II clinical trials for AMD3100, a potential new agent in stem cell transplantation for cancer patients. The first study will evaluate AMD3100, as a single mobilizing agent, in multiple myeloma (MM) patients undergoing a stem cell transplant. The second study will evaluate AMD3100, in combination with the standard mobilization regimen, in patients with Hodgkin’s disease (HD) undergoing a stem cell transplant.

 

December 1, 2004

MIGENIX Second Quarter Fiscal 2005 Financial Results
VANCOUVER, BC, CANADA and SAN DIEGO, CA, USA, Dec. 1 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Wednesday, December 8, 2004 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the second quarter of Fiscal 2005 ended October 31, 2004 and provide an update on company activities.

 

December 1, 2004

INEX and ENZON Announce ODAC Does Not Support Accelerated Approval for Cancer Drug MARQIBOâ„¢
Vancouver, BC and Bridgewater, NJ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“ENZON”; NASDAQ: ENZN) announced today that the Oncology Drugs Advisory Committee (ODAC) of the US Food and Drug Administration (FDA) voted unanimously against recommending accelerated approval for MARQIBOâ„¢ (vincristine sulfate liposomes injection) as a treatment for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL).

 

November 30, 2004

FDA Briefing Documents Posted for MARQIBOâ„¢ for Oncologic Drug Advisory Committee Meeting
Vancouver, BC and Bridgewater, NJ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“ENZON”; NASDAQ: ENZN) announced today that the United States Food and Drug Administration (FDA) has posted on its website briefing documents for the Oncologic Drugs Advisory Committee (ODAC) meeting on Wednesday, December 1, 2004.

 

November 30, 2004

INEX Requests Trading Halt Pending Oncologic Drug Advisory Committee Meeting on MARQIBOâ„¢
Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced earlier today that the United States Food and Drug Administration (FDA) has posted on its website briefing documents for the Oncologic Drugs Advisory Committee (ODAC) meeting to be held on Wednesday, December 1, 2004. In order to provide the greatest opportunity for investors to review the briefing documents, and given that the ODAC hearing will occur during the trading day on Wednesday, December 1, 2004, INEX has requested a trading halt from Tuesday, November 30, 2004 to the end of day on Wednesday, December 1, 2004.

 

November 30, 2004

Allon Completes Pre-Clinical Studies in Preparation for Human Trials
VANCOUVER, Nov. 30 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, reported today its Q3 2004 operating results. In the quarter, the Company completed a successful public equity financing and continued progress in its drug development program remaining on schedule to file an Investigational New Drug (IND) application by the end of 2004. This IND will seek United States Food and Drug Administration (FDA) approval to evaluate the Company’s lead product AL-108 in human clinical trials.

 

November 29, 2004

Cardiome Selects Oral RSD1235 Formulation
Vancouver, Canada, November 29, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) announced that it has chosen a controlled release formulation of oral RSD1235 to take forward for further clinical development. The formulation was chosen based on the successful completion of its recent Phase 1a clinical trial. The study was an open-label, cross-over evaluation of two controlled release formulations of RSD1235 in comparison to an immediate release formulation. Cardiome today initiated a Phase 1b study involving this chosen formulation.

 

November 29, 2004

ONCO-LIFEâ„¢ Installed at BCCA With Dr. Stephen Lam – XILLIX Also Announces Engineering/Quality Appointments
Richmond, B.C. – Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that it has installed Onco-LIFEâ„¢ at the British Columbia Cancer Agency (BCCA) in Vancouver, Canada for use by Dr. Stephen Lam. Dr. Lam is the Chair of the Lung Tumour Group at BCCA, a principal investigator in the Onco-LIFE multi-center lung cancer clinical trial, and co-inventor of Xillix LIFE- Lungâ„¢, the predecessor to the Onco-LIFE device. Onco-LIFE is the Company’s latest device developed for the improved detection of lung and gastrointestinal (GI) cancers. In August, Onco- LIFE was approved for sale in Canada.

 

November 29, 2004

Forbes Medi-Tech Expands Reducol(tm) Business into Scandinavia with Scanvit Ltd, Finland
Vancouver, Canada Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that it has agreed to supply Reducol(tm) for use in milk-based drinks to Scanvit Ltd., a Finnish healthcare company. This is the second international functional food partnership announced since the EU Commission decision was issued earlier this month authorizing the use of Reducol(tm) in milk-based beverages.

 

November 29, 2004

INEX and ENZON Conference Call Notification on ODAC Results
Vancouver, BC and Bridgewater, NJ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“ENZON”; NASDAQ: ENZN) announced today a conference call and webcast will be held on Wednesday, December 1, 2004 after the completion of the Oncologic Drugs Advisory Committee (ODAC) meeting on MARQBIOâ„¢.

 

November 29, 2004

Response Biomedical and 3M Collaborate on Infectious Disease Test
Vancouver, British Columbia, November 29, 2004 – Response Biomedical Corp. (TSX-V: RBM) and 3M Company (NYSE: MMM) through its Medical Division, today announced that the two companies have entered into a co-development agreement whereby 3M will fund the development of a new rapid, point-of-care microbiology test in the area of infection prevention based on Response Biomedical’s RAMP technology. The parties intend to enter into a further supply agreement whereby Response Biomedical will manufacture and 3M will exclusively market a line of microbiology tests.

 

November 26, 2004

Cohesion consolidation update
VANCOUVER, Nov. 26 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today provided an update on the consolidation of Cohesion Technologies announced previously during the Company’s third quarter conference call.

 

November 23, 2004

Boston Scientific Exercises Rights to Exclusive Coronary License
VANCOUVER, Nov. 23 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) announced today that Boston Scientific Corporation has elected to become the exclusive worldwide licensee to Angiotech’s coronary drug-eluting stent technology. Under the terms of the 1997 License Agreement between Boston Scientific and Angiotech, Boston Scientific’s royalty obligation for sales of licensed coronary vascular products (e.g., TAXUS(TM)) will be increased by one percent. This will have the effect of increasing Angiotech’s TAXUS(TM) royalty revenues by approximately 14% (elevating the royalty tiers to 6%, 8%, and 11%, respectively).

 

November 23, 2004

B.C. Medical Innovations Fund Brings a Healthy Boost to B.C.’S Life Sciences Sector
Vancouver – Canadian Venture Capital Management Corporation, jointly owned by MDS Capital Corp. and Dr. Calvin Stiller, announces that it has acquired Altura Management Inc., the Manager of the ALTURA Growth Fund (EVCC) Inc. The ALTURA Growth Fund will be refocused to invest exclusively in British Columbia’s life sciences sector and re-launched as the BC Medical Innovations Fund (BCMIF), bringing a healthy boost to B.C.’s life sciences sector.

 

November 22, 2004

French government expands reimbursement for TAXUSâ„¢ Express2â„¢ paclitaxel-eluting stent system
VANCOUVER, Nov 22, 2004 /PRNewswire-FirstCall via COMTEX/ — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today welcomed an announcement by the French government that it has added new categories of”high-risk” patients to the reimbursement approval criteria for the TAXUSâ„¢ Express2â„¢ paclitaxel-eluting coronary stent system.

 

November 22, 2004

Response Biomedical Announces Key Appointments To Senior Management Team and Board of Directors
VANCOUVER, Nov. 22 /CNW/ – Response Biomedical Corp. (TSX-V: RBM) todayannounced the appointments of Mr. Sidney Braginsky, past President of Olympus America Inc., to the Company’s Board of Directors, and Mr. Robert Pilz,B.Comm., CMA, as Chief Financial Officer and Vice President, Finance, effective immediately.

 

November 22, 2004

Forbes Medi-Tech Signs International Reducol Sales and Licensing Agreement
VANCOUVER, British Columbia–(BUSINESS WIRE)–Nov. 22, 2004–Forbes Medi-Tech Inc. (NASDAQ:FMTI ; TSX:FMI) today announced that it has signed a 5-year sales and licensing agreement with Fayrefield Foods of Crewe, UK to supply Reducol(TM) for use in milk-based drinks. Applications for other food groups are expected to be filed before year-end.

 

November 19, 2004

Forbes Medi-Tech Appoints Dr. Steven Nissen to Chairman of Medical & Scientific Advisory Board
Vancouver, BC — Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ:FMTI) announced today that Dr. Steven Nissen, Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), has been appointed Chairman of Forbes Medi-Tech’s Medical & Scientific Advisory Board (MSAB).

 

November 19, 2004

QLT and Atrix Laboratories Complete Merger
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) and Atrix Laboratories, Inc. (NASDAQ: ATRX) announced today that they have completed their merger transaction, creating a leading global biopharmaceutical company focused on ophthalmology, oncology, dermatology and urology.

 

November 18, 2004

Abgenix to Receive Milestone Payment from CuraGen for Advancement of CR002 Antibody Product Candidate into Clinic
FREMONT, Calif.–(BUSINESS WIRE)–Nov. 18, 2004–Abgenix, Inc. (Nasdaq:ABGX) announced today it will receive a milestone payment from CuraGen Corporation triggered by the advancement of CR002, a fully human antibody created using Abgenix’s proprietary XenoMouse(R) technology, into a Phase 1 clinical trial.

 

November 18, 2004

MIGENIX Appoints Recognized Financial Market Expert, W. Keith Schilit, Ph.D. to Board
VANCOUVER, BC and SAN DIEGO, CA, Nov. 18 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has appointed W. Keith Schilit, Ph.D., to its Board of Directors.

 

November 17, 2004

Stressgen announces Positive Phase II Data in High Grade Cervical Dysplasia
SAN DIEGO, CA, Nov. 17 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today a 40 percent response rate in a 21-patient trial of its lead drug product candidate, HspE7, in high grade cervical dysplasia. Patients in the study were scheduled to undergo Loop Electrocautery Excision Procedure (LEEP), a standard surgical procedure for patients with high grade dysplasia, to remove the affected area and to evaluate the effect of HspE7. This result is an early response rate for HspE7 as the LEEP was performed only two months following the last dose of drug. The trial was sponsored by the Norris Comprehensive Cancer Center of the University of Southern California (USC) in Los Angeles, California.

 

November 16, 2004

enGene Inc. appoints R. Hector MacKay-Dunn and L. Jack Wood to its Board of Directors
Vancouver, British Columbia — 16 November 2004 – enGene Inc., a privately held biotechnology company headquartered in Vancouver, announced today the appointment of two highly experienced healthcare professionals to its Board of Directors, Hector MacKay-Dunn and L. Jack Wood.

 

November 15, 2004

Ondine Biopharma Announces First Quarter 2005 Results
VANCOUVER, Nov. 15 /CNW/ – Ondine Biopharma Corporation (TSX-V: OBP; AIM: OBP) (“Ondine”) announced today its First Quarter 2005 results for the three- month period ended September 30, 2004.

 

November 15, 2004

Cardiome Reports Third Quarter Results
Vancouver, Canada, November 15, 2004 – Cardiome Pharma Corp. (NASDAQ-CRME, COM-TSX) reported today financial results for the third quarter ended September 30, 2004. Effective December 31, 2003, the Company changed its fiscal year end from November 30 to December 31. As a result, the Company has provided comparative results for the three and nine months ended August 31, 2003. Amounts, unless specified otherwise, are in Canadian dollars. At September 30, 2004, the exchange rate was CDN$1.00 = U.S. $0.7926.

 

November 15, 2004

Forbes Medi-Tech Announces Financial Results for the Third Quarter ended September 30, 2004
Vancouver, Canada – Forbes Medi Tech Inc. (TSE:FMI; NASDAQ:FMTI) today announced its financial results for the three and nine-month periods ended September 30, 2004. Comparative periods for these statements are the three months and nine months ended September 30, 2003, respectively. All amounts are in Canadian Dollars unless otherwise noted.

 

November 15, 2004

Wex Initiates Phase IIa Clinical Trial of TetrodoxinTM for Reductionof Withdrawal Symptoms in Opiate Dependent Patients
Wex Pharmaceuticals Inc. (TSX: WXI), is pleased to announce that it has initiated a Phase IIa double-blind, randomized, cross-over, placebocontrolled trial of TetrodinTM (Wex’s proprietary formulation of Tetrodotoxin-TTX). This study is designed to evaluate the safety and efficacy in decreasing the severity of withdrawal symptoms in 20 opiate-dependent subjects who are receiving methadone in a treatment program.

 

November 12, 2004

Chromos announces third quarter 2004 financial results
BURNABY, BC, Nov. 12 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR), a cellular engineering and therapeutics company creating value through engineering production quality cell lines for the manufacture of biopharmaceuticals and developing innovative therapies for infectious diseases, cancer and genetic disorders today announced financial results for the third quarter of fiscal 2004 ended September 30, 2004.

 

November 12, 2004

Angiotech announces preliminary data from pivotal European gynecology anti-adhesion study
VANCOUVER/SAN FRANCISCO, CA, Nov. 12 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced preliminary eight-week follow-up data on 20 patients from a single center in its pivotal European study using Adhibit(TM) to reduce the incidence and severity of adhesions following laparoscopic surgery in a gynecological population.

 

November 12, 2004

EU Commission Decision Approves Reducol(tm) in Milk Based Beverages
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced a European Commission decision has been issued authorizing the use of Forbes’ cholesterol-lowering ingredient, Reducol(tm), in milk-based beverages. The approval of Reducol(tm) in milk-based products creates a major opportunity for Forbes Medi-Tech to attract new contracts, drive revenue growth and increase shareholder value. Plant sterol sales in Europe are estimated to grow at a rate of 15% annually until 2010 in Europe, according to a recent Frost & Sullivan report.

 

November 10, 2004

BC Advantage Funds invests in Allon Therapeutics
Vancouver (November 10, 2004), BC Advantage Funds (VCC) Ltd. (“Advantage”), announced today that it has invested $500,000 into Allon Therapeutics (TSX:NPC) and that its CEO, Frank Holler, has been appointed to the board of Allon. Allon is developing compounds that have demonstrated potent neuroprotective capabilities in pre-clinical studies in a wide range of chronic and acute neurodegenerative conditions including Alzheimer’s, multiple sclerosis, stroke and traumatic brain injury. Allon is expected to commence Phase I clinical trials in humans in 2005.

 

November 10, 2004

US Dept. of Homeland Security Sponsored Evaluation Confirms Superior Performance of Response Biomedical’s RAMP ® Anthrax Test
Vancouver, British Columbia, November 10, 2004 – Response Biomedical Corp. (TSX-V: RBM) today announced the Company’s RAMP ® Anthrax Test is the only rapid biological detection system to meet the new performance standards introduced by AOAC INTERNATIONAL for rapid immunoassay-based anthrax detection systems.

 

November 10, 2004

Wex Pharmaceuticals Inc Reports Financial Results for Second Quarter Ended September 30, 2004
Vancouver, November 8, 2004 – Wex Pharmaceuticals Inc. (TSX: WXI) today reported interim financial results for the three and six month periods ended September 30, 2004. The unaudited interim consolidated financial statements presented here have been prepared in accordance with Canadian generally accepted accounting principles for interim financial information (“Canadian GAAP”). All figures herein are denoted in Canadian dollars unless otherwise specified.

 

November 9, 2004

MIGENIX Presents Data Supporting Efficacy of MX-4565 in Retinitis Pigmentosa
VANCOUVER, BC & SAN DIEGO, CA, Nov. 9 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, recently presented evidence of efficacy of MX-4565, a small molecule with potent neuroprotective activity, in a transgenic model for Retinitis Pigmentosa (RP) at the First International Symposium on Translational Clinical Research for Inherited and Orphan Retinal Diseases in Washington, D.C.

 

November 9, 2004

AnorMED announces fiscal 2005 second quarter results and upcoming key events
VANCOUVER, Nov. 9 /CNW/ – AnorMED Inc. (TSX:AOM) today reported financial results for its second quarter ended September 30, 2004. AnorMED recorded a net loss of $6,584,000 ($0.21 per common share) in this quarter. This is in comparison to the net losses incurred in the second fiscal quarter of 2004 of $4,212,000 ($0.16 per common share) and in the previous quarter, ended June 30, 2004 of $3,814,000 ($0.12 per common share).

 

November 8, 2004

Canada’s Michael Smith Genome Sciences Centre announces the release of OSCAR 4.0
VANCOUVER, British Columbia, November 8, 2004 – Canada’s Michael Smith Genome Sciences Centre (GSC) is pleased to announce that the OSCAR working group has released its latest version of the Open Source Cluster Application Resources (OSCAR) toolkit, version 4.0.

 

November 5, 2004

INEX and Enzon Announce Filing of New Drug Submission to Health Canada
Vancouver, British Columbia – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) announced today that they have filed a New Drug Submission (NDS) with the Therapeutics Products Directorate (TPD) of Health Canada for Marqiboâ„¢ (formerly referred to as Onco TCS).

 

November 5, 2004

Abstracts on AnorMED’s AMD3100 stem cell transplant drug candidate accepted for presentation at the American Society of Hematology Conference
VANCOUVER, Nov. 5 /CNW/ – AnorMED Inc. (TSX:AOM) announced today that a number of clinical and preclinical abstracts on AMD3100, a potential new agent in stem cell transplantation for cancer patients, have been accepted for presentation at the American Society of Hematology (ASH) annual meeting being held in San Diego December 4-7th , 2004.

 

November 4, 2004

Response Biomedical Appoints Dr. Michael Groves as New Vice President of Sales and Marketing
Vancouver, British Columbia, November 4, 2004 – Response Biomedical Corp. (TSX-V: RBM) today announced the appointment of Dr. Michael Groves, former Vice President of International Sales and Marketing for both Abbott Point-of-Care and i-STAT Corporation, to the position of Vice President, Sales and Marketing.

 

November 4, 2004

AnorMED expands AMD3100 stem cell transplant program in cancer patients to include Canada and the European Union
VANCOUVER, Nov. 4 /CNW/ – AnorMED Inc. (TSX:AOM) announced today the initiation of Phase II clinical trials in Canada and the European Union to evaluate AMD3100 as a new stem cell transplantation drug candidate for cancer patients. Clinical data to date in cancer patients shows AMD3100 increases the number of stem cells available for transplantation. The strongest predictor of success in stem cell transplant is the number of stem cells available for transplantation.

 

November 4, 2004

MIGENIX releases CEO message
VANCOUVER, BC and SAN DIEGO, CA, Nov. 4 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, today issued its 13th CEO Message from Jim DeMesa, MD, President & CEO.

 

November 4, 2004

Angiotech Pharmaceuticals, Inc. announces results for the third quarter ended September 30, 2004
VANCOUVER, Nov. 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced financial results for the third quarter ended September 30, 2004. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

November 3, 2004

Cardiome to Present RSD1235 Abstracts at AHA
Vancouver, Canada, November 3, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that three abstracts on its lead antiarrhythmic drug, RSD1235, are scheduled to be presented at the upcoming meeting of the American Heart Association to be held in New Orleans from November 8-11.

 

November 3, 2004

$24.3 Million Research Grant to Further BC Health Care
VICTORIA – Government is investing $24.3 million for health system research and support for the ongoing work of the Michael Smith Foundation for Health Research (MSFHR), Premier Gordon Campbell announced today.

November 1, 2004

Angiotech free to provide exclusive license to Boston Scientific
VANCOUVER, Nov. 1 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act (HSR) has expired pertaining to the proposed grant of an exclusive license to Boston Scientific Corporation with respect to the use of paclitaxel and other agents on medical devices in the coronary vascular field of use.

 

November 1, 2004

Interim Phase 2 Data Suggest Activity of Panitumumab with Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
VIENNA, Austria–(BUSINESS WIRE)–Nov. 1, 2004–Amgen Inc. (Nasdaq:AMGN) and Abgenix (Nasdaq:ABGX) today announced interim data from part one of an ongoing Phase 2 study suggesting panitumumab, the first fully human monoclonal antibody that inhibits the epidermal growth factor receptor (EGFr), has activity as a first-line treatment with chemotherapy in patients with metastatic colorectal cancer (mCRC).

 

October 28, 2004

Angiotech partner announces start of enrollment in ARRIVE 2 drug-eluting stent registry
VANCOUVER, Oct. 27 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“Boston”), today announced the start of enrollment in the ARRIVE 2 registry program, which plans to enroll 5,000 patients at approximately 60 centers in the United States. The program is designed to collect and analyze “real-world” safety and clinical outcomes data from the TAXUS(TM) Express2(TM) paclitaxel-eluting coronary stent system in the treatment of patients with coronary artery disease.

 

October 28, 2004

Angiotech partner first to receive FDA approval allowing immediate MRI exams for its TAXUS(R) Express(2)(TM) paclitaxel-eluting stent system
VANCOUVER, April 5 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“Boston”) today announced that the U.S. Food and Drug Administration (FDA) has approved enhancements to the Directions for Use (DFU) of the TAXUS(R) Express(2)(TM) paclitaxel-eluting coronary stent system, indicating that patients receiving the stent systems may safely undergo Magnetic Resonance Imaging (MRI) examination immediately following implantation.

 

October 28, 2004

Stressgen Biotechnologies announces third quarter 2004 financial results
SAN DIEGO, CA, Oct. 28 /CNW/ – Stressgen Biotechnologies (TSX: SSB) announced today financial results for the third quarter ended September 30, 2004. All amounts, unless specified otherwise, are in Canadian dollars.

 

October 28, 2004

Stressgen appoints Gordon R. Barefoot to Board of Directors
SAN DIEGO, CA, Oct. 28 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that it has appointed financial services industry veteran Gordon R. Barefoot to the Company’s Board of Directors, effective immediately. Mr. Barefoot is the Senior Vice President of Finance and Chief Financial Officer of Terasen, Inc.

 

October 28, 2004

INEX Releases Third Quarter Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (INEX; TSX: IEX) reported today in its third quarter 2004 operating results that it remains focused on working towards United States Food and Drug Administration (FDA) approval of its lead product Marqiboâ„¢ (formerly referred to as Onco TCS) and on advancing its second product INX-0125 into clinical trials.

 

October 28, 2004

Angiotech to webcast conference call discussing third quarter 2004 financial results
VANCOUVER, Oct. 28 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), will webcast its conference call discussing financial results for the third quarter ended September 30th, 2004 on Thursday, November 4th, 2004 at 2:00 PM PST (5:00 PM EST).

 

October 27, 2004

FDA approval of FOSRENOL triggers U.S. $18 million payment to AnorMED Inc.
VANCOUVER, Oct. 27 /CNW/ – AnorMED Inc. (TSX:AOM) announced that they will receive a U.S. $18 million milestone payment from Shire Pharmaceuticals Group, plc based on today’s approval by the U.S. Food and Drug Administration of FOSRENOL as a treatment for high phosphate levels in the blood, which occurs in patients undergoing dialysis as a result of chronic kidney failure.

 

October 27, 2004

Abgenix Announces Third Quarter 2004 Financial Results
FREMONT, Calif., October 26, 2004 – Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the third quarter ended September 30, 2004.

 

October 26, 2004

Cardiome Appoints New Directors
Vancouver, Canada, October 26, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has recently appointed two new independent Directors, Harold H. Shlevin, Ph.D., and Jackie M. Clegg.

 

October 25, 2004

ARC Pharmaceuticals Inc. Presents Results at the American Society for Reproductive Medicine Annual Meeting
VANCOUVER, Oct. 25 /CNW/ – ARC Pharmaceuticals Inc. announced today that Dr. Johanne Cashman, Director of Preclinical Research, presented new data at the American Society for Reproductive Medicine (ASRM) Annual Meeting in Philadelphia, Pennsylvania on October 20, 2004. The presentation was entitled, “The effect of DNA topoisomerase inhibitor-loaded films on postsurgical adhesion formation in the rat.”

 

October 25, 2004

Protox signs exclusive Licence Agreement with Johns Hopkins University and the University of Victoria
Monday, October 25, 2004 – Vancouver, British Columbia – Protox Therapeutics Inc. announced today that it has signed an exclusive licence agreement with Johns Hopkins University (JHU) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). The licence grants Protox the worldwide rights to commercialize a genetically modified Aerolysin protein developed by the research institutions as a targeted therapy for the treatment of prostate cancer.

 

October 25, 2004

International Wex Technologies Inc. Changes Name to Wex Pharmaceuticals Inc.
Vancouver, October 25, 2004 – International Wex Technologies Inc. (TSX: WXI), a pharmaceutical company developing drugs for the management of pain, announces that the Company has changed its name to Wex Pharmaceuticals Inc. (“WEX” or “the Company”). It is expected the shares of the Company will commence trading on the Toronto Stock Exchange under the company’s new name on Wednesday October 27th. The trading symbol will remain the same (WXI).

 

October 21, 2004

Inex Pharmaceuticals Conference Call Notification Third Quarter 2004 Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, October 28, 2004 at 9:00 a.m. PST (12:00 noon EST) to discuss third quarter 2004 operating results and to provide an update on developments at the Company.

 

October 21, 2004

Kinexus Announces New Phosphoprotein Screening Service
VANCOUVER, British Columbia – Kinexus Bioinformatics Corporation, a Canadian proteomics company that provides unique immunoblotting services to over 500 academic and biopharmaceutical laboratories, reported the successful launch of its sixth Kinetworks Phospho-Site Screening Service, KPSS 6.0. The new screen, developed in collaboration with Stressgen Bioreagents in Victoria, Canada, was designed to simultaneously detect the presence and relative quantities of 34 critical protein phosphorylation sites in humans and diverse animal model systems.

October 20, 2004

MIGENIX to Present at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference on October 27th
VANCOUVER, BC, & SAN DIEGO, CA, Oct. 20 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will be presenting at the Rodman & Renshaw Techvest 6th Annual Healthcare Conference in New York City.

 

October 20, 2004

QLT Announces Q3 Results for 2004
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the third quarter ended September 30, 2004. Unless specified otherwise, all amounts are in U.S. dollars and reported under U.S. GAAP.

 

October 19, 2004

Chemokine Therapeutics Corp. Begins Phase I Clinical Trials of CTCE-0214, a Novel Chemokine Targeted Drug for Stem Cell Mobilization
Vancouver, BC, October 19, 2004 – Chemokine Therapeutics Corp. announced today that it has begun Phase I clinical testing to evaluate the safety, pharmacodynamics, and pharmacokinetic profile of CTCE-0214, a drug candidate for the mobilization of hematopoietic stem and progenitor cells into peripheral blood for collection by leukapheresis (a process of selective removal of white blood cells).

 

October 18, 2004

Response Biomedical and Shionogi Collaborate on RAMP BNP Test For Congestive Heart Failure
Vancouver, British Columbia, October 18, 2004 – Response Biomedical Corp. (TSX-V: RBM) today announced a collaboration with Shionogi & Co., Ltd to develop a rapid quantitative RAMP ® test for BNP (B-type natriuretic peptide), a proprietary cardiovascular marker test to assist in the diagnosis and management of congestive heart failure.

 

October 14, 2004

VISUDYNE ® in Occult (VIO) Trial to Continue to Its Conclusion at 24 Months
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it will continue the Visudyne ® (verteporfin for injection) in Occult (VIO) trial to the 24-month endpoint.

 

October 14, 2004

QLT and Atrix Laboratories Joint Proxy Statement Cleared by SEC
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) and Atrix Laboratories, Inc. (NASDAQ: ATRX) announced today that QLT’s registration statement on Form S-4 filed in connection with their proposed merger has been declared effective by the United States Securities and Exchange Commission (SEC). The registration statement includes a joint proxy statement/prospectus that will be sent to the stockholders of both companies.

 

 

October 13, 2004

MIGENIX initiates Hepatitis C Phase II clinical study
VANCOUVER, BC, & SAN DIEGO, CA, Oct. 13 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, has initiated enrollment in its MX-3253 Phase II Hepatitis C Virus (HCV) clinical efficacy study in chronic HCV patients.

 

October 12, 2004

Cardiome Completes ACT 1 Enrolment
Vancouver, Canada, October 12, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has completed patient enrolment in its Phase 3 atrial fibrillation trial, ACT 1. The study measures the safety and efficacy of intravenous RSD1235 in 420 patients with atrial fibrillation or flutter. The last patient was enrolled on October 5, 2004.

 

October 7, 2004

Ondine Biopharma Corporation – Stock Options
 

October 7, 2004

Chromos and Ex Vivo Technologies enter agreement for use of ace system in adult-derived stem cell research
 

October 7, 2004

Neuromed Technologies Announces Appointment of Dr. Mark Corrigan to its Board of Directors
 

October 6, 2004

Chromos announces withdrawal of private placement financing.
BURNABY, BC, Oct. 6 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) today announced that due to current market conditions it will not proceeding with the private placement announced on July 29, 2004.

 

October 5, 2004

Forbes Medi-tech Appoints New Financial Officer
Vancouver, BC — Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ:FMTI) today announced the appointment of David Goold, CA as Chief Financial Officer (CFO) of the Company. Prior to joining Forbes Medi-Tech, Mr. Goold held the position of Vice President and Chief Financial Officer for Vizon SciTec Inc., and its predecessor company BC Research Inc. for six years.

 

October 4, 2004

enGene Inc. to Present at BioContact Quebec 2004
Vancouver, Canada – enGene Inc., a privately held biotechnology company, is scheduled to present on October 6, 2004 at 4:30pm ET (1:30pm PT) at the BioContact Quebec meeting in the Jacques-Cartier room, Chateau Frontenac in Quebec, Canada. BioContact is a partnership symposium where over 150 companies present to more than 1200 participants. Eric A. Adams, President and CEO, will present an overview of enGene’s business, scientific progress and prospects for future development.

 

October 4, 2004

Stressgen Files Canadian Preliminary Prospectus for Offering of Common Shares in Conjunction with U.S. Private Placement
 

 

October 3, 2004

Abgenix Announces Positive Clinical Trial Results for ABX10241
 

 

October 1, 2004

Angiotech partner announces 30-day safety data from its TAXUS V drug-eluting stent clinical trial
VANCOUVER, BC and WASHINGTON, DC, Oct. 1 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“Boston”), today announced 30-day safety data from its TAXUS V clinical trial. The trial is assessing the slow-release formulation of the TAXUS(TM) Express2(TM) paclitaxel-eluting stent system in 1,172 patients at 66 sites in the U.S.

 

October 1, 2004

Company Completes Regulatory Filing
Vancouver, BC — Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ:FMTI) today announced that the audited financial statements of the Company for the year ended December 31, 2003 were filed on SEDAR and EDGAR and were distributed as required by applicable securities regulations in April 2004 (see the Company’s press release dated April 20, 2004). These financial statements were prepared in accordance with Canadian GAAP, and were audited by the Company’s auditors, KPMG LLP, in accordance with Canadian generally accepted auditing standards and auditing standards generally accepted in the United States of America. The financial statements also contained a note reconciling the statements to U.S. GAAP.

 

September 30, 2004

Active Pass Pharmaceuticals, Inc. Receives $3.6 M CDN Grant from NIH for Development of Novel Treatment of Secretory Diarrhea
Active Pass Pharmaceuticals, Inc. today announced receipt of a grant of $ 3.6 M CDN ($2.8 M USD) for development of a novel treatment for secretory diarrhea. The award was made by the National Institute of Allergy and Infectious Diseases (NIAID) branch of the National Institute of Health (NIH) in the United States. Dr. David MacDonald, President and CEO of Active Pass, is the principal investigator.

 

September 30, 2004

Ondine Biopharma Corporation Announces Year End Fiscal 2004 Financial Results
VANCOUVER, Sept. 30 /CNW/ – Ondine Biopharma Corporation (TSX-V: OBP; AIM: OBP) (“Ondine”) announced today its financial results for the year ended June 30, 2004.

 

September 29, 2004

Stressgen Granted Additional Patent Covering Use of Lead Compound, HSPE7
SAN DIEGO, CA, Sept. 29 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that the U.S. Patent and Trademark Office has issued Patent Number 6,797,491, covering the use of HspE7, the Company’s lead product candidate, to treat patients with Recurrent Respiratory Papillomatosis (RRP) caused by the human papillomavirus (HPV).

 

September 29, 2004

Agrisoma enters into collaboration agreement with Dow AgroSciences
BURNABY, BC, and INDIANAPOLIS, IN, Sept. 29 /CNW/ – Agrisoma Biosciences Inc. (“Agrisoma”) and Dow AgroSciences LLC (“Dow AgroSciences”) announced today a collaboration agreement to research, develop and commercialize animal health products using Agrisoma’s patented ACE System. Under the terms of the agreement, Agrisoma will apply its gene delivery and expression technology with Dow AgroSciences plant systems.

September 29, 2004

Boston Scientific announces two-year follow-up data from TAXUS IV clinical trial
VANCOUVER, BC and WASHINGTON, DC, Sept. 29 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“Boston”), today announced two-year follow-up data from its TAXUS IV clinical trial. The benefits reported at 12 months — for patients who received a paclitaxel-eluting stent compared to patients who received a bare-metal stent — were maintained at two years. Boston Scientific made the announcement at the annual Transcatheter Cardiovascular Therapeutics symposium in Washington, D.C.

 

September 29, 2004

Neuro Discovery Closes $18.5- Million Allon Acquisition
VANCOUVER, Sept. 29 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) announced today that it has closed the acquisition of Allon Therapeutics, Inc. for $10.5-millon in equity, as well as converting $8-million in special warrants held in escrow bringing the total deal to $18.5-millon.

 

September 28, 2004

ARC Pharmaceuticals Inc. Raises CDN $1.6 million
VANCOUVER, Sept. 28 /CNW/ – ARC Pharmaceuticals Inc. announced today that it has successfully closed a private financing of CDN $1.6 million. To date, ARC has raised over CDN $3 million through private funding, research grants and investment tax credits.

 

September 28, 2004

Fujisawa to Invest US$4 Million in Cardiome
Vancouver, Canada, September 28, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has exercised its right to place US$4 million of equity at C$7.89 with Fujisawa Healthcare, Inc. (“Fujisawa”). The equity was placed at a 25% premium to the 30 calendar day average market price of $6.31.

 

September 28, 2004

Aspreva’s Leadership Recognized with Prestigious Business Award
Aspreva Pharmaceuticals today announced that CEO Richard Glickman received the Ernst & Young Entrepreneur of the Year 2004 award for the Pacific region Life Sciences Group.

 

September 28, 2004

EnGene Inc. to Present at BIO Emerging Company Investor Forum
Vancouver, Canada – enGene Inc., a privately held biotechnology company, is scheduled to present on October 15, 2004 at 9:50am PT (12:50pm ET) at the BIO Emerging Company Investor Forum (BECIF) in the Telegraph Room, Palace Hotel, in San Francisco. The BECIF is rapidly becoming the leading investor conference for emerging public and private companies in the biotechnology industry and a major opportunity for investors to meet with management of presenting companies.

 

September 28, 2004

MDX Announces Management Changes
For Immediate Release September 28, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) today announced key management changes. Effective immediately, Mr. Mark Thomson succeeds Mr. Barry Allen as President and Director of MDX. Mr. Thomson was formerly Vice-President, Business Development and Marketing. Mr. Allen will continue as Chairman of the Board of Directors.

 

September 27, 2004

MDX Announces Addition of Leading US Cancer Center to AVID Test Program
For Immediate Release September 27 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) Vancouver, Canada – MDX Medical Inc. (TSXV: MDX) is pleased to announce the addition of Harvard Medical School’s Brigham and Women’s Hospital in Boston, MA as the 6th cancer treatment center to beta-test its AVID System, for IMRT (intensity modulated radiation therapy) treatment plan verification.

 

September 27, 2004

INEX and Enzon Announce Marqiboâ„¢ to be Reviewed by FDA’s Oncologic Drugs Advisory Committee
Vancouver, BC and Bridgewater, NJ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) announced today the United States Food and Drug Administration (FDA) will review Marqiboâ„¢, (formerly referred to as Onco TCS), at its upcoming Oncologic Drugs Advisory Committee (ODAC) session scheduled for December 1, 2004. Marqiboâ„¢ is being developed as a single-agent treatment for patients with relapsed aggressive non-Hodgkin’s lymphoma (NHL) previously treated with at least two combination chemotherapy regimens.

 

September 27, 2004

SFU Business Awards Tong Prizes in Entrepreneurship
Business plans touting the benefits of an inexpensive medical diagnostic tool and a new inventory tracking system using radio frequency identification technology were winners for SFU MBA and Executive MBA teams. Each won a $2,000 Tong Prize in Entrepreneurship.

 

September 24, 2004

Cardiome Initiates Oral RSD1235 Patient Dosing
Vancouver, Canada, September 24, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced the initiation of subject dosing in its Phase 1 study of a controlled release formulation of oral RSD1235. The study is an open-label, cross-over evaluation of two controlled release formulations of RSD1235 in comparison to an immediate release formulation. The study will enable Cardiome to evaluate and select which formulation to move forward into further clinical trials.

 

September 24, 2004

Angiotech and Cook Restructure License Agreement
VANCOUVER, Sept. 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) and Cook Incorporated today announced changes to their license agreement regarding paclitaxel-eluting stent products and related technologies. The 1997 Angiotech License Agreement has been restructured to accommodate Cook’s election to exit the coronary vascular field for business reasons and to focus on the development of paclitaxel- eluting peripheral vascular and gastrointestinal stents.

 

September 24, 2004

Wex amends financial Disclosure for the FIRST QUARTER ended June 30, 2004
Vancouver, September 24, 2004 – International Wex Technologies Inc. (TSX: WXI), a pharmaceutical company developing drugs for the management of pain, today announced it has filed amended financial results for the first quarter ended June 30, 2004.

 

September 23, 2004

International Wex Announces Tectin Phase IIA Final Results Presented Today at the 3rd World Congress World Institute of Pain
Vancouver, British Columbia, September 23, 2004 – International Wex Technologies Inc. (TSX: WXI), a pharmaceutical company that develops drugs for the management of pain, today announced the presentation of two posters relating to its Phase IIa study of tetrodotoxin (Tectin), an investigational treatment for the management of severe cancer-related pain, at the 3rd World Congress World Institute of Pain in Barcelona, Spain.

 

September 22, 2004

Bio-IT World Publishes PCIS Biotech Roadmap
Vancouver, Sept. 22 – PCIS (Pacific Coast Information Systems) today announced that its Biotech Roadmap White Paper is featured in the September Issue of Bio-IT World, the leading publication on collaborations between IT and life sciences.

 

September 21, 2004

MIGENIX Inc. completes name change with new trading symbol: MGI
VANCOUVER, BC and SAN DIEGO, CA, Sept. 21 /CNW/ – MIGENIX Inc. (formerly Micrologix Biotech Inc.) (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, will start trading on the TSX under the symbol “MGI” effective at the open on September 21, 2004. This change in trading symbol reflects the name change that was effective September 9, 2004. Trading on the US OTC market will be under the symbol “MGIFF” (formerly “MGIXF”).

 

September 21, 2004

The Book Opens on the First Tree Genome
WALNUT CREEK, CA —An international consortium including the U.S. Department of Energy (DOE), Genome Canada, and the Umeå Plant Science Centre in Sweden, has released the first complete DNA sequence of a tree, Populus trichocarpa, the Black Cottonwood or poplar, one of the most ecologically and commercially valuable group of trees in North America. The sequencing was completed at the DOE Joint Genome Institute Production Genomics Facility.

 

September 21, 2004

Inex Pharmaceuticals to Present at the UBS Life Sciences Conference
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will present at the UBS Life Sciences Conference at The Grand Hyatt Hotel in New York, New York on Tuesday, September 28, 2004 at 1:30 pm EST.

 

September 20, 2004

Xenon and Novartis Sign Drug Development Deal for Obesity and Metabolic Disorders
VANCOUVER, Sept. 20 /CNW/ – Xenon Pharmaceuticals Inc. today announcedthat it has entered into an agreement with Novartis Pharma AG to research,develop and commercialize compounds from Xenon’s Stearoyl-CoA Desaturase-1(SCD1) drug development program. Precommercial payments to Xenon under thistransaction total up to US$157 million. Xenon will also receive royalties onproducts developed from this collaboration.

 

September 17, 2004

OncoGenex Appoints Neil Clendeninn to Board of Directors
VANCOUVER, British Columbia, Canada September 17, 2004 – OncoGenex Technologies Inc. announced today the appointment of Neil Clendeninn, M.D., Ph.D., a biotechnology expert with over 25 years of experience in oncology and medicine, to the company’s Board of Directors.

 

September 17, 2004

Angiotech obtains rights to polymer drug delivery patents
VANCOUVER, Sept. 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it has entered into a transaction pursuant to which it obtains access to patents Guilford Pharmaceuticals Inc. had previously licensed from the Massachusetts Institute of Technology (MIT) and the Johns Hopkins University (JHU). Guilford will receive proceeds of approximately $6.6 million from Angiotech.

 

September 16, 2004

Rachael Froese Joins Genome British Columbia
Rachael Froese has joined Genome British Columbia as Communications Officer. She joins the organization from the Heart and Stroke Foundation of B.C. & Yukon where she has been for three years, lately as Marketing and Communications Officer.

 

September 16, 2004

UBC now home to Canada’s first ‘Green’ research facility
Technology Enterprise Facility III (TEF III) has been awarded a Silver Level Certification from the U.S. Green Building Council’s Leadership in Energy and Environmental Design (LEED) rating system. TEF III is Canada’s first LEED-certified research facility, and only the second building in Canada to achieve a Silver Certification. It is one of only five LEED-certified buildings across the country.

 

September 16, 2004

Cardiome to Present at Investor Conferences
Vancouver, Canada, September 16, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that Bob Rieder, President & CEO, will present at two investor conferences in the coming two weeks. Mr. Rieder will present at the 10th Bioscience Economy Conference on September 20th and 21st in Geneva and Milan. Mr. Rieder will also present at the 2004 UBS Global Life Science Conference on September 30th at 10am EST at The Grand Hyatt in New York. A webcast of Mr. Rieder’s presentation will be available on Cardiome’s website at http://www.cardiome.com/investor/events/.

 

September 15, 2004

Angiotech Pharmaceuticals to participate in Banc of America conference
VANCOUVER, Sept. 15 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Banc of America Securities 34th Annual Investment Conference.

 

September 14, 2004

Cardiome Reports Oxypurinol Clinical Results
Vancouver, Canada, September 13th, 2004 Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) announced today the release of interim results for two physician-sponsored clinical studies for oxypurinol in congestive heart failure (CHF) patients. The results were presented at a satellite symposium to the Heart Failure Society of America’s annual meeting being held in Toronto. Both studies showed a statistically-significant improvement in an important measurement of cardiac function, the left ventricle ejection fraction (LVEF). The LaPlata study showed an improvement of 3.3% in LVEF relative to placebo following 28-day oral dosing of oxypurinol, while the EXOTIC-EF study showed a 3.6% increase in LVEF following IV dosing of oxypurinol.

 

September 14, 2004

BC Innovation Council Announces Winners of 2004 Awards
VANCOUVER – The BC Innovation Council (BCIC) announced the five winners of the 2004 Annual BC Innovation Council Awards today. “We are proud to recognize the outstanding achievements of British Columbia’s science and technology entrepreneurs,” said Cindy Lum, Chief Operating Officer for the newly formed BCIC. “They truly signify the world-class expertise in innovation and leadership that British Columbia is known for.”

 

September 14, 2004

MDX Announces Beta-Test Centers For AVID System
For Immediate Release September 14, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX)Vancouver, Canada – MDX Medical Inc. (TSXV: MDX) is pleased to announce that its AVID System, for IMRT (intensity modulated radiation therapy) treatment plan verification, has been placed in 5 leading cancer treatment centers in the U.S. and Canada for beta-testing prior to market launch later this year.

September 13, 2004

AnorMED to advance AMD3100 to Phase III program for stem cell transplant in cancer patients
VANCOUVER, BC, Sept. 13 /CNW/ – AnorMED Inc. (TSX:AOM) announced today that it will submit its Phase III protocols for AMD3100, its lead drug candidate, to the U.S. Food and Drug Administration (FDA) for special protocol assessment (SPA). AnorMED is evaluating AMD3100 as a potential new agent for stem cell transplant in cancer patients.

 

September 13, 2004

FDA completes Galway inspection; no observations reported
VANCOUVER, Sept. 8 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today announced that the U.S. Food and Drug Administration (FDA) has completed its inspection of Boston Scientific’s Galway, Ireland facility, and that the FDA reported no observations. The inspection began September 1 and ended yesterday, as stated by Boston Scientific.

 

September 9, 2004

Micrologix Reports First Quarter Fiscal Year 2005 Financial Results – – Name Change to MIGENIX Inc. Reflects Transformation
VANCOUVER, BC and SAN DIEGO, CA, Sept. 9 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) reports financial results for the first quarter of Fiscal 2005 ended July 31, 2004.

 

September 9, 2004

Stressgen announces HspE7 trial in internal genital warts
SAN DIEGO, CA, Sept. 9 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced that it has broadened the clinical program for its lead drug candidate, HspE7, through the enrollment of patients in a Phase II clinical trial to investigate HspE7 in patients with internal genital warts, a human papillomavirus (HPV)-related disease. Fifteen of the 30 patients in this trial have been enrolled with completion of enrollment anticipated in October.

 

September 9, 2004

Ventures West Closes Largest Private Venture Capital Fund Ever Raised in Canada
September 14, 2004 – Toronto, ON – Ventures West Management Inc., one of Canada’s largest privately owned venture capital companies, announced that it has closed its eighth venture capital fund at $250 million. The fund, the largest private venture capital fund ever raised in Canada, will invest in early stage technology companies in the biotechnology, communications, energy technology, and information technology sectors.

 

September 8, 2004

Abgenix Appoints H. Ward Wolff as Chief Financial Officer
FREMONT, Calif., Sept. 8, 2004 – Abgenix, Inc. (Nasdaq: ABGX) today announced the appointment of H. Ward Wolff as Chief Financial Officer and Senior Vice President, Finance, effective September 13.

 

September 8, 2004

Forbes Medi-Tech Announces US$24.4 Million in Sterols Sales Agreement
Vancouver, British Columbia –Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that it has secured a sterols sales agreement for US$24.4 million over a three-year period beginning in January 2005. This new customer agreement is between Forbes’ manufacturing joint venture, Phyto-Source LP, and a leading multinational ingredient company. For contractual reasons, the identity of the new customer and contractual terms and conditions, will not be disclosed.

 

September 8, 2004

Dr. Johanne Cashman, ARC Pharmaceuticals Inc., Publishes Paper in Inflammation Research Describing Novel Treatment for Prevention of Postsurgical Adhe
VANCOUVER, Sept. 9 /CNW/ – ARC Pharmaceuticals Inc. announced today that Dr. Johanne Cashman, Director of Preclinical of Research, published a paper entitled “Camptothecin-loaded Films for the Prevention of Postsurgical Adhesions” in the August 2004 issue of Inflammation Research.

 

September 7, 2004

Cardiome to Present at Investor Conferences
Vancouver, Canada, September 7, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that Bob Rieder, President & CEO, will present at two upcoming conferences in September. The first, the 11th Annual NewsMakers in the Biotech Industry Conference in New York City, will be held on September 9th. Mr. Rieder’s presentation will be from 2:30pm to 2:55pm EST. A webcast of the presentation will be available on Cardiome’s website at http://www.cardiome.com/investor/events/.

 

September 7, 2004

Micrologix receives approval to initiate Phase II study of MBI-3253 (celgosivir) in Hepatitis C patients
VANCOUVER, BC, and SAN DIEGO, CA Sept. 7 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) has received a Letter of Authorization for its clinical trial application (CTA) from Health Canada to begin a Phase IIa human clinical study with MBI-3253 (celgosivir), an oral first-in-class therapy in development for the treatment of chronic Hepatitis C Virus (HCV) infections. Study site selection has been completed, with the study expected to begin enrolling patients within the next few weeks and results expected in the second quarter of calendar 2005.

 

September 7, 2004

IBM Healthcare and Life Sciences Announces Matthew Simone as their new Life Sciences Client manager
Marie-Josee Normand, Business development manager, IBM Healthcare and Life Sciences would like to announce Matthew Simone as their new Life Sciences Client manager for the Western area.

September 7, 2004

Micrologix Biotech First Quarter Fiscal 2005 Financial Results Conference Call & Web Cast Notification
VANCOUVER, BC, CANADA and SAN DIEGO, CA, USA, Sept. 7 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) will host a conference call and web cast on Thursday, September 9, 2004 at 9:00 a.m. ET (6:00 a.m. PT) to discuss financial results for the first quarter of Fiscal 2005 ended July 31, 2004 and provide an update on company activities.

 

September 2, 2004

Angiotech Pharmaceuticals to participate in Thomas Weisel Partners Healthcare Tailwinds Conference
VANCOUVER, Sept. 2 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Thomas Weisel Partners Healthcare Tailwinds 2004 Conference.

 

September 1, 2004

Ondine Appoints New President and CEO
VANCOUVER, Sept. 1 /CNW/ – Ondine Biopharma Corporation (TSX-V:OBP,AIM:OBP) (“Ondine”) announces the appointment of Douglass C. Watson to the position of the President and Chief Executive Officer of the Company, effective September 1, 2004.

 

August 31, 2004

Micrologix Completes MitoKor Acquisition
VANCOUVER, BC, CANADA and SAN DIEGO, CA, USA, Aug. 31 /CNW/ – Micrologix Biotech Inc. (“Micrologix”) (TSX: MBI; OTC: MGIXF), a developer of drugs for the prevention and treatment of infectious diseases, has completed the acquisition of San Diego-based MitoKor, Inc. (“MitoKor”), a biotechnology company focused on the treatment of major degenerative diseases related to mitochondrial dysfunction.

 

August 31, 2004

Angiotech partner announces Milestone II Registry reaffirms positive safety outcomes of TAXUS(TM) Express(2)(TM) stent system
VANCOUVER, Aug. 31 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today announced six-month clinical findings from the European component of its Milestone II Registry. Boston Scientific said it has enrolled nearly 3,700 patients worldwide in the registry, which has been designed to assess physician usage patterns and evaluate outcome data for the TAXUS(TM) Express(2)(TM) paclitaxel-eluting coronary stent system in “real world” patients.

 

August 31, 2004

Cardiome Analyst Day
Vancouver, Canada, August 31, 2004 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it will hold an analyst day on Monday September 13, 2004 from 1:00pm to 3:00pm EST. The event will feature presentations focusing on Cardiome’s Congestive Heart Failure program and will include a discussion period. The analyst day will follow Cardiome’s satellite symposium at the Heart Failure Society of America conference on September 12th, “Xanthine Oxidase Inhibition for the Treatment of Congestive Heart Failure”.

 

August 30, 2004

Neuro Discovery Inc. Announces Second Quarter 2004 Results
VANCOUVER, Aug. 30 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) is pleased to announce the unaudited financial and operating results of the three months ended June 30, 2004.

 

August 30, 2004

QLT Reiterates Confidence in Visudyne’s Potential
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) reiterated its confidence in Visudyne(R)’s potential in the treatment of age-related macular degeneration (AMD). The company also reiterated its 2004 guidance of Visudyne sales of US$430 to $455 million and its post-integration guidance for the combined QLT-Atrix company of a cash EPS compound annual growth rate of 20-25%. This statement is made following the U.S. Food and Drug Administration (FDA) advisory panel for the anti-VEGF aptamer which was held on Friday, August 27th.

 

August 30, 2004

Response Biomedical Receives Canadian Regulatory Clearance
Vancouver, British Columbia, August 30, 2004 – Response Biomedical Corp. (TSX-V: RBM) today announced that it has received clearance from Health Canada’s Therapeutic Products Directorate to market two additional RAMP ® Cardiac Marker Tests for detecting troponin I and CK-MB to assist in the rapid diagnosis of heart attack or acute myocardial infarction (AMI), a leading cause of death worldwide. The Company has now received US Food and Drug Administration (FDA) and Canadian regulatory clearance for its fluorescence-based RAMP ® Reader for general clinical use, and all three RAMP Cardiac Marker Tests for detecting troponin I, CK-MB and myoglobin.

 

August 26, 2004

Angiotech partner announces enrollment of first patient in clinical trial for next-generation paclitaxel-eluting coronary stent system
VANCOUVER, Aug. 26 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today announced that enrollment has begun in Boston Scientific’s ATLAS clinical trial. ATLAS is the first trial using Boston Scientific’s new Liberte(TM) coronary stent as a platform for its paclitaxel-eluting coronary stent system. TAXUS(TM) Liberte(TM) will be the next generation to Boston Scientific’s current paclitaxel-eluting coronary stent system, TAXUS(TM) Express(2)(TM). The Liberte stent, which has been designed to further enhance deliverability and conformability, particularly in challenging lesions, is currently available in international markets in a bare metal version.

 

August 26, 2004

Xillix Receives Health Canada Approval for Onco-Lifeâ„¢
Richmond, B.C., August 26, 2004 – Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that it has received its Medical Device License from Health Canada for Onco-LIFEâ„¢. Onco-LIFE is the Company’s latest device, incorporating Xillix LIFEâ„¢ fluorescence endoscopy technology with conventional white-light endoscopy. Onco-LIFE has been developed for the early detection and localization of cancer, including lung cancer and gastrointestinal (GI) cancers. This Health Canada license allows Xillix to begin selling Onco-LIFE in Canada.

 

August 26, 2004

Wex Announces Clinical Study for Tetrodin / Reports on Progress with U.S. Pain Program
Vancouver, August 24, 2004 – International Wex Technologies Inc. (TSX: WXI), a pharmaceutical company developing drugs for the management of pain, today announced that it has filed an amended study with Health Canada to conduct a Phase II clinical trial in Canada for Tetrodin, for the treatment of opioid drug withdrawal. The study was originally filed in 2002 and granted clearance by Health Canada to proceed.

 

August 24, 2004

Linda Bartz Joins Genome British Columbia as Director, Communications and Education
VANCOUVER, B.C. – August 24, 2004 – Dr. Alan Winter, President and CEO of Genome British Columbia is pleased to announce the appointment of Linda Bartz to the position of Director, Communications and Education.

 

August 19, 2004

FDA approves extension of expiration date for TAXUSâ„¢ Express2â„¢ paclitaxel-eluting stent system to nine months
VANCOUVER, Aug 19, 2004 – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of its TAXUS Express2 paclitaxel-eluting coronary stent system in the United States to nine months from the current shelf life of six months. The decision was based on data submitted by Boston Scientific to the FDA that demonstrated the performance of the TAXUS system – in particular the drug content, drug degradation profile, and drug-release mechanism – was maintained within FDA- approved specifications at nine months.

 

August 19, 2004

Chromos Enters into Agreement with Centocor For Development of Cell Lines For Production of Therapeutic Proteins
Burnaby, British Columbia, Canada – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that is has entered into a collaborative agreement with Centocor Inc., of Malvern, Pennsylvania, a wholly owned subsidiary of Johnson & Johnson, to develop cell lines using the Artificial Chromosome Expression (ACE) System for potential use in the clinical and commercial manufacture of two undisclosed therapeutic proteins.

 

August 18, 2004

MDX Announces Successful Pre-Market Launch of AVID System
For Immediate Release August 18, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) MDX Medical Inc. (TSXV: MDX) is pleased to report the successful pre-market launch of the Company’s AVID System, for IMRT (intensity modulated radiation therapy) treatment plan verification, at the AAPM (American Association of Physicists in Medicine) conference held July 25 to 29th in Pittsburgh, PA. At this conference, attended by over 1,700 medical physicists and other radiation therapy specialists, MDX provided demonstrations of the AVID System to potential customers and accepted initial offers of interest. MDX Medical will officially launch the AVID System into the U.S. market in October 2004.

 

August 17, 2004

International Wex Reports Financial Results for First Quarter Ended June 30, 2004
Vancouver, August 17, 2004 – International Wex Technologies Inc. (TSX: WXI) today reported interim financial results for the first quarter of fiscal 2005 (three months ended June 30, 2004 ). The comparative period for these statements is the first fiscal quarter of 2004 (three months ended June 30, 2003 ). All amounts are in Canadian dollars unless otherwise specified.

 

August 16, 2004

Inflazyme Pharmaceuticals Ltd. Announces Financial Results for the Quarter Ended June 30, 2004
Vancouver, BC, August 16, 2004–Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announces financial results for the first quarter ended June 30, 2004. This was a quarter of significant events for the Company culminating in the recently announced re-alignment of the Company’s R&D strategy and restructuring.

 

August 16, 2004

Micrologix Receives Permit from State of California To Proceed with MitoKor Acquisition
Vancouver, BC, August 16, 2004–Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) was issued a Permit from the Department of Corporations of the State of California to proceed with the acquisition of MitoKor, Inc. pursuant to a public fairness hearing held on August 11, 2004 at the Department of Corporations in Los Angeles, California. The Permit was one of the major conditions to be satisfied prior to completing the acquisition of MitoKor and, among other things, allows the shares of Micrologix stock issuable in connection with the acquisition to be exempt from registration under the United States Securities Act of 1933.

 

August 16, 2004

International Wex reports results for the fiscal year ended March 31, 2004
Vancouver, August 16, 2004 – International Wex Technologies Inc. (TSX: WXI) today reported financial results for the year ended March 31, 2004. The comparative period for these statements is the 12 months ended March 31, 2003. All amounts are in Canadian dollars unless otherwise specified.

 

August 13, 2004

Chromos announces second quarter 2004 results
BURNABY, BC, Aug. 13 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR), a leader in the development and commercialization of immune- and gene-based cell therapies and cell line engineering for biopharmaceutical production, today announced financial results and operational highlights for the second quarter ended June 30, 2004.

 

August 13, 2004

Abgenix to Receive Milestone Payment From Amgen
FREMONT, Calif., August 13, 2004 – Abgenix, Inc. (Nasdaq:ABGX) announced today that it will receive a milestone payment from Amgen triggered by the advancement of AMG 162, a fully human antibody created using Abgenix’s proprietary XenoMouse ® technology, into a pivotal clinical trial.This is one of seven antibodies derived from XenoMouse technology that are currently in clinical trials by Abgenix and its various partners, and the first product candidate from Abgenix’s technology out-licensing program to move into the pivotal phase of development.

 

August 12, 2004

Chromos announces executive appointments
BURNABY, BC, Aug. 12 /CNW/ – Chromos Molecular Systems Inc. (“CHROMOS”; TSX:CHR) announced today the appointments of Dr. Phillip B. Maples as Vice President, Clinical Development and Manufacturing, Dr. Alan Hardwick as Vice President, Process Development and Kathryn Hayashi as Vice President, Finance.

 

August 12, 2004

Forbes Medi-Tech Announces Financial Results for the Second Quarter ended June 30, 2004
Vancouver, Canada – Forbes Medi Tech Inc. (TSE:FMI; NASDAQ:FMTI) today announced its financial results for the three and six-month periods ended June 30, 2004. Comparative periods for these statements are the three months and six months ended June 30, 2003, respectively. All amounts are in Canadian Dollars unless otherwise noted.

August 12, 2004

Neuro Discovery Closes $7.94-Million Private Placement
VANCOUVER, Aug. 12 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) announced today that it has closed a $7.94-million private placement of special warrants that convert into 7,943,000 shares and 3,971,500 non-transferable warrants upon closing of the intended acquisition of Allon Therapeutics, Inc. Each warrant will be exercisable into one share at a price of $1.25 until February 12, 2006.

 

August 10, 2004

Cardiome to Webcast Q2 Financial Results
Vancouver, Canada, August 10th, 2004 Cardiome Pharma Corp (NASDAQ: CRME, TSX: COM) today announced that it will release second quarter financial results on Thursday August 12th at 4:00 p.m. EST (1:00 p.m. PST). Cardiome will hold a teleconference and webcast that same day to discuss the results and to provide an update on developments of the Company. The conference call will be held at 4:30 p.m. EST (1:30 p.m. PST), please dial 416-695-5261 or 1-877-667-7774 to access the call. There will be a separate dial-in line for analysts on which we will respond to questions at the end of the presentation. The live or archived webcast can be accessed through either http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=880440 or the “What’s New” section of Cardiome’s website at www.cardiome.com.

 

August 10, 2004

Kinexus Bioinformatics Corporation Announces the Appointment of Two New Directors to its Board
VANCOUVER, Aug. 10 /CNW/ – Kinexus Bioinformatics Corporation, is pleased to announce the appointments of Mr. Justin Stephenson and Mr. Joel Bellenson to the Board of Directors of Kinexus. “We are delighted to welcome these two high-caliber executives to our Board,” said Dr. Steven Pelech, Founder, President and Chief Scientific officer of Kinexus. “Both individuals bring over twenty years of experience in the healthcare and high technology industries and in-depth knowledge of these sectors. Their expertise in finance, corporate and business development will greatly facilitate realization of our corporate objectives as Kinexus embarks on its next growth phase”.

 

August 10, 2004

AnorMED announces fiscal 2005 first quarter results and upcoming key events
VANCOUVER, Aug. 10 /CNW/ – AnorMED Inc. (TSX:AOM) today reported financial results for its first quarter ended June 30, 2004. AnorMED recorded a net loss of $3,814,000 ($0.12 per common share) in this quarter. This is comparable to the net losses incurred in the first fiscal quarter of 2004 of $4,979,000 ($0.19 per common share) and in the previous quarter, ended March 31, 2004, of $3,931,000 ($0.12 per common share).

 

August 9, 2004

Ondine Commences Trading on the AIM Exchange
VANCOUVER, Aug. 9 /CNW/ – Ondine Biopharma Corp. (TSX-V:OBP) (“Ondine”) announced today that the Company’s common shares have commenced trading on the London Stock Exchange’s Alternative Investment Market (AIM) under the Symbol “OBP”. Canaccord Capital (Europe) Limited has been appointed as Nominated Adviser and broker to the Company.

 

August 9, 2004

Angiotech Pharmaceuticals, Inc. announces results for the second quarter ended June 30, 2004
VANCOUVER, Aug. 9 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX:ANP) today announced financial results for the second quarter ended June 30, 2004. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

August 6, 2004

Angiotech completes acquisition of NeuColl
VANCOUVER, Aug. 6 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it has completed its acquisition of NeuColl, Inc., for an all-cash transaction of US$12,894,950. NeuColl is a privately-held orthobiologics company based in Los Gatos, California. Previously, Angiotech had obtained an equity interest in NeuColl through the acquisition of Cohesion Technologies, Inc. on January 31, 2003.

 

August 6, 2004

Ondine Biopharma Announces Third Quarter Fiscal 2004 Financial Results
VANCOUVER, Aug. 6 /CNW/ – Ondine Biopharma Corp.(TSX-V:OBP) (“Ondine”) announces its financial results for the third quarter and nine-month period ended March 31, 2004.

 

August 5, 2004

Neuro Discovery Announces Private Placement Terms
VANCOUVER, Aug. 5 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) announced today the terms of its forthcoming private placement. The intent to seek a private placement was published on June 21, 2004 when NDI announced its agreement in principle to acquire all of the outstanding securities of Allon Therapeutics, Inc. and to merge the two companies’ operations in a transaction considered by the TSX Venture Exchange to be a Change of Business.

 

August 5, 2004

Stressgen Biotechnologies announces second quarter 2004 financial results
SAN DIEGO, CA, Aug. 5 /CNW/ – Stressgen Biotechnologies (TSX: SSB)announced today financial results for the second quarter ended June 30, 2004.

 

August 5, 2004

Angiotech partner expands recall of TAXUS coronary stent system
VANCOUVER, Aug. 5 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific, today provided an update on the TAXUS(TM) Express(2TM) Paclitaxel-Eluting Coronary Stent System. On July 2 and 16, Boston Scientific announced the voluntary recall of certain TAXUS and Express(2TM) coronary stent systems, due to characteristics in the delivery catheters that had the potential to impede balloon deflation during a coronary angioplasty procedure, a condition known as focal neckdown, and which could result in serious injury to patients.

 

August 4, 2004

GENOME BRITISH COLUMBIA CALL FOR PROPOSALS UNDER GENOME CANADA COMPETITION III
Genome British Columbia wishes to bring to your attention the announcement of Competition III by Genome Canada. The Guidelines and Evaluation Criteria for the competition are available on Genome Canada’s website at http://www.genomecanada.ca.

 

August 4, 2004

GlaxoSmithKline Provides Notice to Terminate Topotecan Agreement
VANCOUVER – Inex Pharmaceuticals Corporation (INEX; TSX:IEX) announced today that it has received notice that GlaxoSmithKline (GSK; LSE and NYSE:GSK) will terminate the agreement to develop liposomal topotecan (INX-0076) effective September 1, 2004. As part of the agreement, GSK can terminate with 30 days written notice.

 

August 3, 2004

Micrologix and Strata Pharmaceuticals Complete License Agreement for MBI-226
VANCOUVER and SAN DIEGO, CA, Aug. 3 /CNW/ – Micrologix Biotech Inc. (“Micrologix”) (TSX: MBI; OTC: MGIXF), and Strata Pharmaceuticals, Inc., (“Strata”) a private, hospital-focused specialty pharmaceutical company based in San Diego, have entered into a Collaboration and License Agreement for the development and commercialization of MBI-226, a compound in Phase III clinical development for the prevention of catheter-related infections.

 

August 3, 2004

AnorMED conference call notification – 1st Quarter 2005 Results and Update
VANCOUVER, Aug. 3 /CNW/ – AnorMED Inc. (TSX: AOM) announced today that it will hold a conference call and web cast on Tuesday, August 10, 2004 at 1:30 p.m. PST (4:30 p.m. EST) to discuss 1st quarter 2005 operating results and to provide an update on developments at the company. The live and archived web cast can be accessed through the company’s web site at www.anormed.com.

 

July 29, 2004

Forbes Medi-Tech Announces the Addition of Two Novel Cholesterol Absorption Inhibitors to its Drug Development Pipeline
Vancouver, BC — Forbes Medi-Tech Inc. (TSE:FMI; NASDAQ:FMTI) today announced the addition of two novel cholesterol absorption inhibitors to its drug development program. Plans for the US Phase II clinical study of its lead compound, FM-VP4, were announced earlier this month, with an expected Q2 2005 start date.

 

July 29, 2004

INEX Releases Second Quarter Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (INEX; TSX: IEX) reported today in its second quarter 2004 operating results the achievement of two significant milestones towards the commercialization of its lead anticancer product Onco TCS as well as progress on earlier stage products.

 

July 29, 2004

Angiotech Pharmaceuticals to participate in Adams, Harkness & Hill Summer Seminar
VANCOUVER, July 29 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the 24th Annual Adams, Harkness & Hill Summer Seminar.

 

July 29, 2004

Chromos announces proposed private placement financing
Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) today announced that it has engaged Raymond James Ltd., Orion Securities Inc. and Haywood Securities Inc. as its agents to assist Chromos to complete a private placement of up to 10,769,231 Units at a price of $0.65 per Unit, for aggregate gross proceeds of up to $7,000,000.

 

July 28, 2004

Abgenix Announces Second Quarter 2004 Financial Results
FREMONT, Calif.–(BUSINESS WIRE)–July 27, 2004–Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the second quarter ended June 30, 2004.

 

July 28, 2004

Angiotech partner to begin first U.S. clinical trial of a drug-eluting non-coronary stent
VANCOUVER, July 28 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) corporate partner Cook Incorporated, announced today that Cook will begin the first U.S. clinical trial of a drug-coated stent for a peripheral (non-coronary) artery. The study will examine whether drug-coated stents, which have shown clinical success in treating coronary artery disease, can have similar benefits in treating peripheral vascular disease.

 

July 28, 2004

Chromos Completes Acquisition of CellExSys Inc.
BURNABY, BC, July 28 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that it has completed its acquisition of CellExSys Inc. (“CellExSys”). Chromos issued 1.5 million common shares and a convertible debenture in principal amount of Cdn $3.375 million in exchange for all of the issued and outstanding shares of CellExSys.

 

July 28, 2004

Inflazyme Pharmaceuticals Announces Re-aligned R&D Strategy Undertaking Restructuring to Focus Resources
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it is implementing a plan to re-focus its Research and Development efforts to concentrate primarily on its Complement Inhibition and Prodaptinâ„¢ technologies.

 

July 28, 2004

Kinexus Validates PLK1 as a Cancer Drug Target
FOR IMMEDIATE RELEASE – Vancouver, British Columbia. Kinexus Bioinformatics Corporation, a Canadian proteomics company, is pleased to announce the validation of its unique approach for protein kinase drug target discovery with the publication of its latest research findings in the September printed issue of the Journal of Biological Chemistry (currently available in JBC Online: M403264200).

 

July 27, 2004

Angiotech Pharmaceuticals to participate in Banc of America conference
VANCOUVER, July 23 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Banc of America Securities 2004 Specialty Pharmaceuticals Conference.

July 26, 2004

Inex Pharmaceuticals Conference Call Notification 2004 Second Quarter Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, July 29, 2004 at 9:00 a.m. PST (12:00 noon EST) to discuss 2004 second quarter operating results and to provide an update on developments at the Company.

 

July 26, 2004

International Wex Announces Tectin Phase II trial begins in China
International Wex Technologies Inc. (the Company) is pleased to announce that the Tectin Phase II clinical trial in China has commenced to demonstrate the analgesic efficacy of Tectin in patients with chronic cancer pain. This is an efficacy trial in which an initial phase of escalating dose to the effective dose (Part I) is followed by a controlled phase (Part II). The total participants for Part I and Part II are approximately 300 patients, and will involve up to 8 SFDA (State Food and Drug Administration) authorized centers across China.

July 23, 2004

StemCell Technologies And Applied Imaging Corp. Renew Exclusive Agreement To Supply Non-Magnetic Cell Separation Technology For Detecting Circulating
VANCOUVER, BC, Jul 26, 2004 – StemCell Technologies announced today that Applied Imaging Corp. has renewed its exclusive supply agreement with StemCell for the use of StemCell’s novel RosetteSep ® reagent technology in the isolation of circulating tumor cells in the blood of cancer patients. The isolation and analysis of circulating tumor cells, frequently associated with metastatic cancer, may have clinical value in determining prognosis, response to therapy or the most appropriate monitoring strategies for certain cancers.

 

July 22, 2004

Stressgen Presents Data at International Immunology Congress
MONTREAL, July 22 /CNW/ – Stressgen Biotechnologies Corporation (TSX:SSB) today presented data at the 12th International Congress of Immunology demonstrating that HspE7, the Company’s lead immunotherapeutic, induces strong and durable cellular responses to the human papillomavirus (HPV) E7 protein in normal and immunocompromised mice.

 

July 22, 2004

QLT Announces Q2 Results for 2004
Vancouver, Canada–QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the second quarter ended June 30, 2004. Unless specified otherwise, all amounts are in U.S. dollars and reported under U.S. GAAP.

 

July 22, 2004

Angiotech Partner receives FDA approval for clinical trial of its Liberte(TM) paclitaxel-eluting coronary stent system
VANCOUVER, July 22 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today reported that its corporate partner, Boston Scientific Corp. announced today that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to begin its ATLAS clinical trial. ATLAS is the first clinical trial using Boston Scientific’s new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. TAXUS(TM) Liberte will be the next generation to Boston Scientific’s current paclitaxel-eluting stent system, TAXUS(TM) Express(2)(TM).

 

July 21, 2004

Gabe Kalmar Joins Genome British Columbia as Executive Director, Operations
VANCOUVER, B.C. – July 19, 2004 – Dr. Donald Riddle, Chief Scientific Officer of Genome British Columbia, is pleased to announce the appointment of Gabe Kalmar to the position of Executive Director, Operations.

 

July 20, 2004

QLT Announces Visudyne(R) Sales For Second Quarter of 2004
VANCOUVER, CANADA–QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of US$109.3 million for the quarter ended June 30, 2004. This represents an increase of 22.6% over sales in the second quarter of 2003.

July 20, 2004

INEX Presents Data From New Immunotherapy Product Showing Synergistic Anti-tumor Effect in Combination with Monoclonal Antibodies
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) today presented research results that indicate its pre-clinical Targeted Immunotherapy product, INX-0167, has the potential to enhance the anti-tumor activity of monoclonal antibodies. Monoclonal antibodies are used in cancer treatment to kill or inhibit the growth of malignant cells. Over the past few years a number of monoclonal antibodies have been approved to treat a variety of different cancers.

 

July 20, 2004

MBI-3253 (celgosivir) Demonstrates Potent Activity Against Hepatitis C Virus Surrogate
VANCOUVER, July 20 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) announces the publication of results demonstrating the potent efficacy of MBI-3253 (celgosivir) against the widely accepted surrogate model of the Hepatitis C Virus (“HCV”), bovine viral diarrhea virus (“BVDV”). BVDV is closely related to HCV and is an in-vitro predictor of the efficacy of anti- HCV drugs in humans.

 

July 20, 2004

Abgenix Appoints William R. Ringo as New CEO and President
FREMONT, Calif.–(BUSINESS WIRE)–July 20, 2004–Abgenix, Inc. (Nasdaq:ABGX) today announced the appointment of William R. Ringo as CEO and President effective August 30, following Ray Withy’s decision to step down.

 

July 16, 2004

Angiotech Partner to Recall Additional Coronary Stent Systems
VANCOUVER, July 16 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today reported that its corporate partner, Boston Scientific Corp. announced today that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS(TM) Express2(TM) Paclitaxel- Eluting Coronary Stent Systems. Boston Scientific is also beginning a voluntary recall of certain units of its Express2(TM) Coronary Stent Systems (bare metal stents). Boston Scientific has notified the U.S. Food and Drug Administration (FDA) and plans to notify officials in other affected countries.

 

July 14, 2004

Ondine Biopharma increases Private Placement
VANCOUVER, July 14 /CNW/ – Ondine Biopharma Corp. (TSX-V:OBP) (“Ondine”) announces the sale of an additional 444,450 common shares under its Private Placement, previously announced on June 30, 2004, to Canadian, European and U.S. institutions. The sale of the additional common shares yielded gross proceeds of $1,000,012.50. In aggregate the Company sold 7,976,116 common shares at C$2.25 per share, yielding gross proceeds of C$17,946,261 under the private placement.

July 13, 2004

Natalie Dakers Appointed to Genome British Columbia Board of Directors
VANCOUVER, B.C. – July 13, 2004 — Dr. Alan Winter, President and CEO of Genome British Columbia announces the appointment of Natalie Dakers — a leading figure in the biotechnology industry in Canada — to the Genome BC Board of Directors.

 

July 13, 2004

Protox Completes Qualifying Transaction and Raises $4.5 Million Offering Oversubscribed by 50%
VANCOUVER, July 13 /CNW/ – Protox Therapeutics Inc., formerly SNB Capital Corp., (“Protox”) today announced that it has completed its Qualifying Transaction and closed a $4.5 million public financing. The financing was led by Wellington West Capital Inc. and IPC Securities Corporation. Protox announced it intended to carry out a $3.0 million public financing; however, demand for the offering led Protox and its agents to increase the size of the financing to $4.5 million. It is expected that shares in Protox will resume trading on the TSX Venture Exchange on July 14, 2004 under the new symbol “PRX”.

 

July 12, 2004

Micrologix Reports Fourth Quarter and Fiscal Year 2004 Financial Results
VANCOUVER, July 12 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) reports financial results for the fourth fiscal quarter ended April 30, 2004.

 

July 9, 2004

Cardiome Congestive Heart Failure Trial to Continue
Vancouver, Canada, July 9 2004, Cardiome Pharma Corp (NASD: CRME, TSX: COM) today announced that it’s independent Data Safety Monitoring Board (DSMB) has issued a recommendation to continue the phase 2 randomized controlled clinical trial, OPT-CHF, evaluating oxypurinol as an add-on treatment for class III-IV Congestive Heart Failure. The Cardiome DSMB unanimously voted to continue the study. The recommendation was based on the first planned safety analysis of data from the first subset of patients to complete the 24 week trial and a review of safety data from all patients currently enrolled in the trial.

 

July 9, 2004

AnorMED announces new HIV entry inhibitor drug candidate to advance to Phase II clinical program
VANCOUVER, July 9 /CNW/ – AnorMED Inc. (TSX:AOM) announced today that positive clinical data from healthy volunteers support continued clinical development of AMD070, as new anti-HIV therapy, in a Phase Ib/IIa program. The Company’s clinical program for AMD070 is being conducted in collaboration with leading investigators at the U.S. Adult AIDS Clinical Trials Group, which is supported by the National Institute of Allergy and Infectious Diseases at the National Institute of Health.

July 9, 2004

International Wex Technologies Announces Appointment of New CFO
International Wex Technologies (the Company) is pleased to announce the appointment of Dave Matthews as its new Chief Financial Officer. Bruce Hay will relinquish his role as the Chief Financial Officer and assume the position as Chair of the Audit Committee. Bruce will also remain as a Director of the Company.

 

July 8, 2004

Chromos gains license from Lonza Biologics for production host cell line
 

July 8, 2004

Forbes Medi-Tech Clears Key Regulatory Hurdle for Reducol(tm) Approval in Europe
 

July 8, 2004

 
Haywood teams with biotech experts to offer life sciences fund
 

July 7, 2004

Neuromed Technologies Announces New President & CEO, Dr. Christopher Gallen
 

 

July 7, 2004

Micrologix Biotech Fourth Quarter & Year End Financial Results Conference Call & Web Cast Notification
 

 

July 7, 2004

Third Phase 3 Study Initiated for Cardiome’s Atrial Arrhythmia Product
 

 

July 6, 2004

Forbes Medi-Tech Announces FM-VP4 Development Plan
 

 

July 6, 2004

Inimex Pharmaceuticals Inc. Announces Series A Venture Capital Financing
 

 

July 6, 2004

Angiotech closes $25 million equity investment in Orthovita
 

 

July 2, 2004

Angiotech partner announces recall of 200 TAXUS(TM) stent systems
 

 

June 30, 2004

Study first to firmly establish causes and progression of COPD
Vancouver, June 23, 2004 A study led by researchers at Providence Health Care has provided the most conclusive answers to date on the causes of Chronic Obstructive Pulmonary Disease. The study’s results are published this week in the New England Journal of Medicine US.

 

June 30, 2004

Stressgen Announces End-of-Phase II Meeting with FDA
 

 

June 29, 2004

Cardiome To Trade on NASDAQ
 

 

June 29, 2004

Forbes Medi-Tech Announces Increase in Revenue Guidance Based on Growth in Sterol Sales
 

 

June 29, 2004

Xenon Genetics Inc. Changes Name to Xenon Pharmaceuticals Inc.
 

 

June 28, 2004

Angiotech completes enrollment of its pivotal vascular wrap study
 

 

June 25, 2004

Medarex to Buy Canadian Biotech Firm Ability Biomedical
 

 

June 24, 2004

Cardiome Receives FDA Approvable Letter on Oxypurinol for Gout
Vancouver, Canada, June 24, 2004 Cardiome Pharma Corp (TSX: COM) today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for oxypurinol for allopurinol-intolerant hyperuricemia (gout). The letter states that prior to final marketing approval, the FDA requires additional clinical and manufacturing data from Cardiome.

 

June 24, 2004

Angiotech addresses growth prospects for 2004, 2005 and 2006
VANCOUVER, June 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today hosted a meeting with analysts and investors in New York and addressed the Company’s revenue and earnings prospects for the years ending December 31 2004, 2005 and 2006. Amounts, unless specified otherwise, are expressed in US dollars.

 

June 24, 2004

Angiotech Introduces COSTASIS ®(VITAGELâ„¢) to Orthopedic & Spinal Surgery Market Through Distribution Agreement with Orthovita Concurrent $25 Million Eq
 

 

June 24, 2004

Angiotech Enters Fast Growing Orthopedic and Spinal Surgery Arena Through Acquisition of NeuColl
 

 

June 23, 2004

StemCell Technologies announces new optimized products for endothelial cell research.
 

 

June 22, 2004

Neuro Discovery Proposes Merger with High Potential Biotech — Allon Therapeutics, Inc.
 

 

June 22, 2004

Chromos Enters into Agreement to Acquire CellExSys
 

June 18, 2004

Response Biomedical Undertaking $3 Million Private Placement
VANCOUVER, June 18 /CNW/ – Response Biomedical Corp. (TSX-V: RBM), todayannounces that it is undertaking a non-brokered private placement of 3,750,000units at a price of $0.80 per unit, each unit consisting of one common shareand one-half of one common share purchase warrant. Each whole warrant shallentitle the holder thereof to purchase one common share of the Company at aprice of $1.15 per share for a period of 24 months from the closing date ofthe private placement. The Company will pay a finder’s fee of 6.67 percent.

 

June 18, 2004

Inflazyme Reports Negative Outcome of Phase IIa Asthma Trial; Company to Focus on Recently Acquired Technologies
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced the results of the Phase IIa study comparing its LSAIDâ„¢ (Leukocyte Selective Anti-Inflammatory Drug),IPL512,602 against placebo in patients with mild to moderate asthma. This was a clinical proof of concept study carried out and paid for by Inflazyme’s partner Aventis.

 

June 17, 2004

Angiotech Pharmaceuticals to webcast analyst meeting
VANCOUVER, June 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI;TSX: ANP) will host a live webcast of its analyst meeting on Thursday, June 24, 2004 beginning at 9:00 am EST (6:00 am PST) and concluding at approximately 5:00 pm EST (2:00 pm PST). The webcast will be available to all interested parties at Angiotech’s website at www.angiotech.com in the Investor Relations section. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes before the webcast begins.

 

June 16, 2004

AVID to Launch at American Association of Physicists in Medicine Conference
Vancouver, Canada – MDX Medical Inc. (TSXV: MDX) is pleased to announce that the US Food and Drug Administration (FDA) has now confirmed that the AVID System qualifies as a Class I device and therefore does not require a 510(K) Premarket Notification submission requirements. In early 2004, the Company submitted documentation on the AVID System to the FDA Center for Devices and Radiological Health (CDRH) to seek an exemption to pre-market submission requirements. Certain standard documentation will be filed with the CDRH as part of required practice and procedure for all medical devices marketed to the US and regulated by the FDA.

 

June 15, 2004

International Wex Announces US$5.1 Million Convertible Debentures Closed
International Wex Technologies (Wex or the Company) is pleased to announce thatit’s wholly owned subsidiary, Wex Medical Limited, has issued unsecured convertibledebentures in the aggregate principal amount of US$5.1 million to 3 investmentfunds managed by a major Asian financial institution’s fund management companyand its affiliates. The principal terms of the Debentures were previously disclosedin the Company’s news release dated May 17, 2004.

 

June 14, 2004

QLT Inc. and Atrix Laboratories Inc. Combine to Create Leading Profitable Biopharmaceutical Company
QLT Inc. and Atrix Laboratories Inc. Combine to Create Leading Profitable Biopharmaceutical Company Focused on Ocular, Oncology, Dermatology and Urology with Rich Portfolio of Products, Pipeline and Drug-Delivery Technologies; Stock and Cash Transaction Estimated at $855 Million

 

June 10, 2004

Angiotech Completes Enrollment of Paclitaxel-Loaded Vascular Wrap Study
 

 

June 10, 2004

Veteran Health Care Banker Thomas Bailey Joins Angiotech as Vice President of Business Development
 

 

June 9, 2004

MDX MEDICAL APPOINTS NEW DIRECTORS
 

 

June 9, 2004

Cardiome to Present at the Needham & Company Thrid Annual Biotechnology Conference
 

 

June 8, 2004

MDX MEDICAL CLOSES $1.3 MILLION PRIVATE PLACEMENT
 

 

June 8, 2004

Micrologix releases CEO Message
VANCOUVER, June 8 /CNW/ – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF), today issued its 12th CEO Message from Jim DeMesa, MD, President & CEO.

June 8, 2004

Angiotech Pharmaceuticals to participate in Thomas Weisel Partners Growth Forum 6.0 Conference
 

 

June 8, 2004

International Wex Announces Manufacturing and Option Agreement Remains Unchanged
As Novartis AG (NYSE:NVS) announced yesterday that Sandoz, a Novartis company has acquired Sabex Holdings Ltd.; International Wex Technologies Inc. (Wex or the Company) is pleased to announce that the Manufacturing and Option Agreement the Company has with Sabex will remain unchanged and Sabex will continue to manufacture Wex’s clinical lots. With this acquisition, Sandoz will now hold the first right of refusal to acquire an exclusive license for Wex’s injectable products in Canada.

 

June 7, 2004

INEX and Enzon Present Promising Follow-up Data at American Society of Clinical Oncology Showing Onco TCS Potential in First-line Lymphoma
 

 

June 7, 2004

AnorMED announces new drug candidate helps multiple myeloma patients collect sufficient number of stem cells for tandem stem cell transplantation
 

 

June 7, 2004

Aspreva Initiates Phase III Trial with CellCept for Myasthenia Gravis
 

 

June 6, 2004

OncoGenex and Isis Pharmaceuticals Announce Compelling Data from Phase I Prostate Cancer Study at ASCO Annual Meeting
VANCOUVER, British Columbia, Canada and CARLSBAD, CA, USA June 6, 2004 – OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today the results of a Phase I study showing that once weekly intravenous administration of OGX-011 is well tolerated, achieves excellent drug concentration in target tissue, and produces a 91 percent dose-dependent down-regulation of its target, clusterin, in prostate cancer. Clusterin is a cell survival protein that, when overproduced, prevents cancer cell death and counters the effectiveness of standard anti-tumor treatments. OGX-011 is a second-generation antisense drug being developed to sensitize tumors resistant to existing treatments such as chemotherapy, hormone ablation therapy and radiation therapy. K. N. Chi, M.D., Study Chair and a medical oncologist at BC Cancer Agency presented the data today at the 40th Annual Meeting of the American Society of Clinical Oncology in N

 

June 3, 2004

Forbes Achieves Major Milestone Towards New Zealand & Australian Approval of Reducolâ„¢
 

 

June 3, 2004

Micrologix enters into exclusive license negotiation period to partner MBI-226
 

 

June 3, 2004

Angiotech to host year-in-review presentation from 2004 Annual General Meeting of Shareholders
 

June 2, 2004

QLT Collaborates with the National Eye Institute to Develop Preservative-free Triamcinolone
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has entered into a Cooperative Research and Development Agreement(CRADA) with the National Eye Institute (NEI) to study the effects of preservative-free triamcinolone acetonide (PFTA) as an adjunct to Visudyne(R) therapy in patients with wet age-related macular degeneration (AMD).

 

June 2, 2004

The Food And Drug Administration (FDA) Accepts Chemokine Therapeutics Corp’s’ Investigational New Drug (IND) Application For Its Stem Cell Mobilizatio
 

 

June 2, 2004

Active Pass Pharmaceuticals, Inc. announces promotion of David MacDonald
 

 

June 1, 2004

AnorMED announces Fiscal 2004 results and 2005 key events
VANCOUVER, June 1 /CNW/ – AnorMED Inc. (TSX:AOM) reported today a net loss of $17,531,000 ($0.64 per common share) for the fiscal year ended March 31, 2004, compared to a net loss of $20,437,000 ($0.80 per common share) in Fiscal 2003. For the fourth quarter of Fiscal 2004, the Company reported a net loss of $3,931,000 ($0.12 per common share) compared to a net loss of $5,391,000 ($0.21 per common share) for the fourth quarter last year.

 

May 28, 2004

Cardiome Presents to FDA Advisory Committee
Vancouver, Canada, May 28, 2004 Cardiome Pharma Corp (TSX: COM) today announced that it is presenting information to the FDA Arthritis Drugs Advisory Committee on June 2, 2004. The meeting will take place in Rockville, MD from 8am-5pm EST.

 

 

May 27, 2004

Forbes Medi-Tech Appoints Don Buxton as Chairman of the Board
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that the Board of Directors has appointed Mr. Donald (Don) Buxton as Chairman of the Board. Don has been a director of Forbes since December 2000. Tazdin (Taz) Esmail, one of the founders of the Company, has resigned his position of Director and Chairman of the Board to focus on his other business interests. Mr. Esmail has been a director of the Company since March 1992 and Chairman of the Board since July 2000.

 

May 26, 2004

Angiotech partner announces sub-population data from its TAXUS VI drug-eluting stent trial
VANCOUVER, May 26 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, today reported that its corporate partner, Boston Scientific Corp. announced nine-month sub-population data from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe, assessing the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics.

 

May 26, 2004

AnorMED conference call notification – 4th Quarter and Year End Results and Update
VANCOUVER, May 26 /CNW/ – AnorMED Inc. (TSX: AOM) announced today that it will hold a conference call and web cast on Tuesday, June 1, 2004 at 1:30 p.m. PST (4:30 p.m. EST) to discuss 4th quarter and Year End operating results and to provide an update on developments at the company. The live and archived web cast can be accessed through the company’s web site at www.anormed.com.

 

May 26, 2004

BC Advantage Raises Over $2 Million of $10 Million Allocation
Vancouver (May 26, 2004), BC Advantage Funds (VCC) Ltd. (“Advantage”), one of the fastest growing funds in the history of British Columbia, has raised over $2 million of its $10 million 2004 tax credit allocation, with more than $1 Million being received in the last two weeks. The BC Government has allocated sufficient tax credits to Advantage to allow it to raise $10 million in equity capital for each of the 2004, 2005 and 2006 tax years. These tax credits provide Advantage investors with a 30% refundable tax credit on investments of up to $200,000 per year (maximum $60,000 annual tax credit). Combined with the $12.3 million Advantage raised for the 2003 taxation year, and its upcoming acquisition of Qwest Emerging Biotech (VCC) Funds, Advantage now has the ability to grow to over $46 million in equity capital within the next three years.

 

May 26, 2004

Vancouver Coastal Health Research Institute (VCHRI) and Prime Trials Inc. Enter into Cooperative Services Agreement to provide Phase I through IV clin
Vancouver, BC, May 26, 2004 – The Vancouver Coastal Health Research Institute (VCHRI) and Prime Trials Inc. have signed a Cooperative Services Agreement to provide non-exclusive integrated Phase I through Phase IV clinical trial services to pharmaceutical and biotechnology companies. The two organizations will also work together to pursue joint marketing opportunities.

 

May 25, 2004

Response Biomedical Receives US FDA Clearance For Third RAMP ® Cardiac Marker Test
Vancouver, British Columbia, May 25, 2004 – Response Biomedical Corp. (TSX-V: RBM), today announced that it has received regulatory clearance from the US Food and Drug Administration (FDA) to market its RAMP* Cardiac Marker Test for detecting CK-MB to assist in the rapid diagnosis of heart attack or acute myocardial infarction (AMI).

 

May 25, 2004

Angiotech partner announces positive results from its TAXUS VI drug-eluting stent trial
VANCOUVER, May 25 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, today reported that its corporate partner, Boston Scientific Corp. announced nine-month results from its TAXUS VI clinical trial. The trial enrolled 448 patients at 44 sites in Europe, assessing the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels and diabetics. Boston made the announcement at the annual Paris Course on Revascularization, the largest interventional cardiology conference in Europe.

 

May 25, 2004

QLT Inc. leader wins Communicator of the Year with open, honest communications
Vancouver, BC – Exemplary communication practice by those outside of the profession is recognized each year by the BC Chapter of the International Association of Business Communicators (IABC/BC). Paul Hastings, President and CEO of QLT Inc., has been selected as the IABC/BC’s 2004 Communicator of the Year.

 

May 24, 2004

DuPont & Seed Veteran to Lead Next Phase of CellFor Development
VANCOUVER, May 24 /PRNewswire/ — CellFor Inc., a forest seed company, has named Thomas N. Urban as the company’s Chief Executive Officer, effective immediately. “CellFor has matured from the research and testing stage to full production,” said Chris J. Worthy, retiring CEO of CellFor. “As CellFor enters this next phase in our corporate life, we are very pleased to have Tom’s leadership and expertise, particularly in the area of high- volume commercial seed production and the marketing of high- value germplasm.”

 

May 21, 2004

INEX and Enzon Announce FDA Acceptance of Onco TCS New Drug Application
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) announced today that the New Drug Application (NDA) for Onco TCS (vincristine sulfate liposomes injection) has been accepted by the United States Food and Drug Administration (FDA) and has been granted a Standard Review designation. Based on this designation, the FDA has established a target date of January 15, 2005 for completion of review of the Onco TCS NDA.

 

May 21, 2004

INEX Makes Milestone Payment to Elan
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that the acceptance of the Onco TCS New Drug Application (NDA) by the US Food and Drug Administration (FDA) triggered the Company’s obligation to make a US$2.5 million payment to its former joint venture collaborator, Elan Corporation, plc (“Elan”; NYSE: ELN). INEX, at its discretion, can make this payment in cash or shares of INEX.

 

May 20, 2004

Angiotech Pharmaceuticals nominates former Medtronic Vice Chairman Dr. Glen Nelson to Board of Directors
VANCOUVER, May 20 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, today announced that Dr. Glen D. Nelson, the former Vice Chairman of Medtronic has accepted the Company’s nomination for election as a director at its upcoming general meeting.

May 20, 2004

Response Biomedical Receives US FDA Clearance For RAMP(R) Cardiac Marker Test
VANCOUVER, May 20 /CNW/ – Response Biomedical Corp. (TSX-V: RBM), today announced that it has received regulatory clearance from the US Food and Drug Administration (FDA) to market an additional RAMP Cardiac Marker Test for detecting troponin I to assist in the rapid diagnosis of heart attack or acute myocardial infarction (AMI), a leading cause of death worldwide.

May 19, 2004

Cardiome to Present at UBS Global Specialty Pharmaceuticals Conference
Vancouver, Canada, May 19, 2004 – Cardiome Pharma Corp. (COM-TSX) reported today that Doug Janzen, Chief Financial Officer, will present highlights of Cardiome’s clinical and corporate achievements at the UBS Global Specialty Pharmaceuticals Conference on Tuesday May 25th from 2:30 to 3:00 p.m. EST at the Grand Hyatt Hotel, New York.

 

May 19, 2004

Neuro Discovery Inc. Announces First Quarter 2004 Results
VANCOUVER, May 19 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) is pleased to announce the unaudited financial and operating results of the three months ended March 31, 2004.

 

May 18, 2004

Vancouver Coastal Health Research Institute (VCHRI) and Syreon Corporation to provide Integrated Clinical Trial Service Offerings
Vancouver, BC, May 18, 2004 – The Vancouver Coastal Health Research Institute (VCHRI) and Syreon Corporation (Syreon) have signed a Cooperative Services Agreement to provide clinical trial solutions on a non-exclusive basis to biotechnology and pharmaceutical companies. The two organizations will also work together to pursue joint marketing opportunities.

 

May 18, 2004

Inex Pharmaceuticals to Present at the UBS Specialty Pharmaceuticals Conference
VANCOUVER, May 18 /CNW/ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will present at the UBS Global Specialty Pharmaceuticals Conference at The Grand Hyatt Hotel in New York, New York on Tuesday, May 25, 2004 at 10:00 am EST.

 

May 17, 2004

Cardiome to Webcast Q1 Financial Results
Vancouver, Canada, March 17, 2004 Cardiome Pharma Corp (TSX: COM) today announced that it will hold a teleconference and webcast on Tuesday, May 18, 2004 at 1:00 p.m. EST (10:00a.m. PST) to discuss the first quarter financial results and to provide an update on developments of the Company. To listen to the conference call, please dial 1-877-667-7774 or 416-695-5261. There will be a separate dial-in line for financial analysts on which we will answer questions at the end of the presentation. The live or archived webcast can be accessed through either or the “What’s New” section of Cardiome’s website at www.cardiome.com.

May 17, 2004

Cardiome Reports First Quarter Results
Vancouver, Canada, May 17, 2004 – Cardiome Pharma Corp. (COM-TSX) reported today financial results for the first quarter ended March 31, 2004. Effective December 31, 2003, the Company changed its fiscal year end from November 30 to December 31. As a result, the Company has provided comparative results for the three months ended February 28, 2003. Amounts, unless specified otherwise, are in Canadian dollars. At March 31, 2004, the exchange rate was CDN$1.00 = U.S. $0.7626.

 

May 17, 2004

International Wex Technologies Inc. Announces US$5.1 Million Convertible Debenture
International Wex Technologies Inc.(Wex or the Company) is pleased to announce that its wholly owned subsidiary, Wex Medical Limited, has agreed in principle to issue unsecured convertible debentures in the aggregate principal amount of US$5.1 million (the Debentures) to major Asian financial institutions. This issue is non-brokered and no commissions or finders’ fee will be payable.

 

May 17, 2004

Forbes Medi-Tech announces Financial Results for the Quarter ended March 31, 2004
Vancouver, Canada – Forbes Medi-Tech Inc. (TSE:FMI; NASDAQ:FMTI) today announced its financial results for the three months ended March 31, 2004. Comparative periods for these statements are the three months ended March 31, 2003. All amounts are in Canadian Dollars unless otherwise noted.

 

May 14, 2004

Chromos announces first quarter 2004 results
BURNABY, BC , May 14 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”;TSX: CHR), a global leader in the development and commercialization of chromosome-based technologies, today announced financial results and operational highlights for the first quarter ended March 31, 2004.

 

May 14, 2004

Inflazyme not to progress further development of GH9001
VANCOUVER, British Columbia–(BUSINESS WIRE)–May 13, 2004–Inflazyme Pharmaceuticals Ltd. (TSX: IZP – News) today announced that, following completion of its Phase Ib, multiple dose clinical trial with the antithrombotic GH9001, the product will not be progressed into further development. The product was being developed with partner LEO Pharma. Resources will now be directed instead towards Inflazyme’s core anti-inflammatory programs.

 

May 13, 2004

MDX Medical Announces Changes in Management
For Immediate Release May 12, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX) announces that effective May 11, 2004 the Board of Directors accepted the resignation of Dr. Linda Allison from the position of President and CEO. Dr. Allison will continue to contribute to the Company as Vice-President, Corporate Development where she will focus on strategic planning and acquisition of new technologies. The Board wishes to thank Dr. Allison for her contributions in the past year in leading the growth of the Company.

May 13, 2004

INEX Releases First Quarter 2004 Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) reported today in its first quarter 2004 operating results that achievement of two major milestones has advanced the Company toward its goals of commercializing its lead product Onco TCS and becoming a fully integrated biopharmaceutical company.

 

May 13, 2004

Angiotech Pharmaceuticals to participate in Banc of America Health Care Conference
VANCOUVER, BC, May 13 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Banc of America Securities 2004 Health Care Conference. William Hunter, President and CEO of Angiotech, will be making a 25-minute presentation at the conference on Thursday, May 20th, 2004 at 12:00 pm PST (3:00 pm EST).

 

May 13, 2004

Dragon Reports Strong First Quarter Results of 2004
VANCOUVER, May 13 /CNW/ – Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB:DRUG) is pleased to announce the results for the first quarter ending March 31, 2004. During the quarter, the Company posted revenues of $878,270 from the sales of rHu Erythropoietin (EPO), which represents 32.2% growth from the same period in 2003.

 

May 11, 2004

Ventures West Continues to Expand Entrepreneur in Residence Team
May 11, 2004 – Vancouver, BC – Ventures West Management Inc., one of Canada’s largest privately owned venture capital companies, is pleased to announce the addition of Barry Allen as Entrepreneur in Residence. Mr. Allen, former President & CEO of VSM MedTech Ltd. will be involved in identifying and evaluating investment opportunities, with a focus on biotech and medical device companies.

 

May 10, 2004

Angiotech Pharmaceuticals, Inc. announces results for the first quarter ended March 31, 2004
VANCOUVER, May 10 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI;TSX: ANP) today announced financial results for the first quarter ended March 31, 2004. Amounts, unless specified otherwise, are expressed in U.S. dollars.

May 7, 2004

International Wex Technologies’ Tectin Study Results Show Efficacy in Pain Management
VANCOUVER, British Columbia – May 7, 2004 – International Wex Technologies TSX: WXI today released the final results of its Phase IIa study of tetrodotoxin (Tectin), an investigational treatment for the management of severe cancer-related pain, at the 2ndJoint Scientific Meeting of the American Pain Society and the Canadian Pain Society being held in Vancouver, BC May 6 – 9, 2004.

 

May 7, 2004

Chromos releases fiscal 2003 results
(“Chromos”; TSX: CHR), a global leader in the development and commercialization of chromosome-based technologies, today announced its financial results for the fiscal year ended December 31, 2003.

 

May 7, 2004

Cardiome’s Data Safety Monitoring Board Recommends Continuation of Phase 3 Atrial Arrhythmia Trial
Vancouver, Canada, May 7, 2004 Cardiome Pharma Corp (TSX: COM) today announced that it’s independent Data Safety Monitoring Board (DSMB) has issued a recommendation to continue the phase 3 clinical trial, ACT 1, evaluating intravenous RSD1235 as a treatment for acute atrial fibrillation (AF) and atrial flutter. The DSMB found no safety concerns that would require protocol changes and recommended that the trial continue.

 

May 6, 2004

Stressgen Biotechnologies Announces First Quarter 2004 Financial Results
SAN DIEGO, CA, May 6 /CNW/ – Stressgen Biotechnologies Corporation (TSX: SSB) announced today financial results for the first quarter ended March 31, 2004. All amounts, unless specified otherwise, are in Canadian dollars.

 

May 6, 2004

Inex Pharmaceuticals Conference Call Notification 2004 First Quarter Operating Results
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, May 13, 2004 at 9:00 a.m. PST (12:00 noon EST) to discuss 2004 first quarter operating results and to provide an update on developments at the Company.

 

May 5, 2004

International Wex Technologies Announce Start of Pivotal Phase IIb/III Trial of Tectin for Cancer Pain
Investigators involved in the pivotal clinical trial of Tectin enrolled and dosed the first of up to 150 patients that will participate in the study. It is one of the largest Canadian clinical trials to evaluate the efficacy and safety of a drug for treatment of medically refractory cancer pain, and will take place in up to 25 treatment centres across Canada.

 

May 5, 2004

Inex Pharmaceuticals Corporation Webcast Notification Annual General Meeting
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX:IEX) announced today that it will webcast its Annual General Meeting on Wednesday, May 12, 2004 at 1:30 PM. PST (4:30 PM EST).

 

May 4, 2004

Avian flu genome sequence provides important new information
The BC Cancer Agency’s Genome Sciences Centre (GSC), the BC Centre for Disease Control (BCCDC) and the Animal Health Centre, Ministry of Agriculture, Food and Fisheries (AHC) have worked together to complete the sequence of the genome of the Influenza A virus implicated in the ongoing Avian Influenza outbreak. Genome information should help to better understand how and why this virus has had such a devastating effect on infected poultry in the Fraser Valley.

 

April 29, 2004

Clera’s Award Highlights Innovation in Mental Illness Treatment
Clera Inc., a Canadian drug discovery company tackling schizophrenia and depression, today was presented BIOTECanada ¹s Promising Early Stage Company Award. BIOTECanada is the national association of the biotechnology industry and research community in Canada representing over 400 companies.

April 29, 2004

Xillix Announces First Quarter 2004 Results
Richmond, B.C. – Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced results for the first quarter ended March 31, 2004. Throughout 2004, the Company will remain focused on the global commercialization of its latest product, Onco-LIFE which incorporates Xillix’s unique fluorescence endoscopy together with conventional white-light endoscopy and has been developed for the improved detection and localization of lung and gastrointestinal (GI) cancers.

 

April 28, 2004

Chromos’ Spin Off Agrisoma Biosciences Closes Series A Financing And Announces President And CEO
Burnaby, British Columbia, Canada- (“Chromos”; TSX: CHR) and its subsidiary Agrisoma Biosciences Inc. (“Agrisoma”) announced today that Agrisoma has completed a Series A round of financing to advance the development of its chromosome-based gene delivery and expression platform in plants. Agrisoma will employ its technology for the development of value enhanced traits in crops and for the production of proteins in plant-based systems.

 

April 27, 2004

QLT ANNOUNCES Q1 RESULTS FOR 2004 AND UPDATES GUIDANCE
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported financial results for the first quarter ended March 31, 2004, and updated guidance for 2004. Unless specified otherwise, all amounts are in U.S. dollars and reported under U.S. GAAP.

 

April 27, 2004

Angiotech Pharmaceuticals to participate in Deutsche Bank Health Care Conference
VANCOUVER, April 27 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Deutsche Bank Securities 29th Annual Health Care Conference.

 

April 27, 2004

AnorMED announces new appointment to Board of Directors
VANCOUVER, April 27 /CNW/ – AnorMED Inc. announced today that Dr. Felix Baker, Managing Partner of Baker Brothers Investments and a Managing Member of Baker Bros. Advisors, LLC, has been appointed to AnorMED’s Board of Directors.

April 27, 2004

Abgenix Announces First Quarter 2004 Financial Results
FREMONT, Calif.–(BUSINESS WIRE)–April 27, 2004–Abgenix, Inc. (NASDAQ:ABGX) today reported financial results for the first quarter ended March 31, 2004.

 

April 23, 2004

QLT ANNOUNCES REIMBURSEMENT FOR VISUDYNE(R) IN JAPAN FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that Visudyne(R) (verteporfin), currently the only treatment for some forms of “wet” age-related macular degeneration (AMD), was reimbursed today in Japan. Visudyne was approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) in October 2003 for the “wet” form of AMD with all types of subfoveal choroidal neovascularization (CNV).

 

 

April 22, 2004

QLT ANNOUNCES VISUDYNE ® SALES FOR FIRST QUARTER OF 2004
VANCOUVER, CANADA–QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne ® (verteporfin) sales of approximately US$101.1 million for the quarter ended March 31, 2004. This represents an increase of 23% over sales in the first quarter of 2003.

 

April 22, 2004

Dragon Announces Worldwide Licensing Rights, excluding China, For Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF)
VANCOUVER, April 22 /CNW/ – Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced that it has entered into an agreement with Suzhou Zhongkai Bio-Pharmaceuticals Company Limited (“Zhongkai”) to in-license the exclusive right to commercialize its Recombinant Human Granulocyte Colony Stimulating Factor (“rhG-CSF”) product worldwide, excluding the People’s Republic of China (the “Agreement”).

 

April 22, 2004

Dragon Pharmaceutical Inc. Announces 2003 Fourth Quarter and Full Year Results
VANCOUVER, April 22 /CNW/ – Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2003.

 

April 22, 2004

Cardiome to Present at CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical Conference
Vancouver, Canada, April 22, 2004 – Cardiome Pharma Corp. (COM-TSX) reported today that Doug Janzen, Chief Financial Officer, and Alan Ezrin, Chief Scientific Officer, will present highlights of Cardiome’s clinical and corporate achievements at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceutical conference.

 

April 22, 2004

MDX MEDICAL ANNOUNCES PRIVATE PLACEMENT FINANCING
For Immediate Release April 22, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX)Vancouver, Canada – MDX Medical Inc. (TSXV: MDX) announces that it has arranged a non-brokered private placement of up to 4,000,000 units at $0.33 per unit for gross proceeds of up to $1,320,000.

 

April 20, 2004

Forbes Medi-Tech announces Financial Results for the Year ended December 31, 2003
Vancouver, Canada – Forbes Medi-Tech Inc. (TSE:FMI; NASDAQ:FMTI) today announced its financial results for the year ended December 31, 2003 versus the year ended December 31, 2002. All amounts are in Canadian Dollars unless otherwise noted.

 

April 19, 2004

Forbes Medi-Tech Announces Additional European Phase II Trial Data for FM-VP4
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced, further to the Company’s April 5th news release and conference call, details from the additional data recently received from the European Phase II clinical trial of its cholesterol-lowering compound, FM-VP4. During the study and as previously indicated, FM-VP4 demonstrated a dose-response that was statistically significant. The data suggests that 400 mg/day may be the optimal dose, although further studies are required to confirm a plateau.

 

April 16, 2004

MICROLOGIX TO ACQUIRE SAN DIEGO-BASED MITOKOR, INC.
Vancouver, BC, CANADA and San Diego, CA, USA – April 15, 2004 – Micrologix Biotech Inc. (“Micrologix”) (TSX: MBI; OTC: MGIXF) has entered into a definitive agreement to acquire San Diego-based MitoKor, Inc. (“MitoKor”), a privately held biotechnology company focused on the research and development of drugs for the treatment of major medical conditions related to mitochondrial dysfunction, with clinical and preclinical product candidates in Alzheimer’s, arthritis, Parkinson’s, and other diseases.

April 15, 2004

$2.5 Million to advance Genomics research and commercialize spin-off technologies
The Honourable Dr. Rey D. Pagtakhan, Minister of Western Economic Diversification, today announced more than $2.5 million in total funding for three projects with Genome British Columbia to support new research and help market existing genome-based technology to the world.

April 15, 2004

INEX Announces Assignment of Elan Promissory Notes to Institutional Investors
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it has been advised that an aggregate of US $27,015,000 in principal amount of promissory notes issued by a subsidiary of INEX to a subsidiary of Elan Corporation, plc has been assigned to a group of U.S. and Canadian institutional investors. GMP Securities Ltd. acted as principal acquiring the notes from Elan’s subsidiary and resold them to the investors. INEX understands that a majority of the notes were acquired by U.S. institutions.

 

April 14, 2004

Forbes Medi-Tech Announces Second Milestone Completion for Reducol(tm) Sales in Europe
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that the European Commission has published regulations concerning the labeling of foods and food ingredients with added phytosterols, phytostanols or their respective esters. The regulation will allow consumers to choose different food formats containing phytosterol ingredients, including Forbes’ cholesterol-lowering ingredient Reducol(tm).

 

April 14, 2004

Angiotech extends exclusive licensing agreement with Poly-Med for biomaterial technologies
VANCOUVER, April 14 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focusing on drug-coated medical devices and biomaterials, today announced that it has licensed a portfolio of biomaterial, drug delivery, and medical device technologies from Poly-Med, Inc. This agreement will expand Angiotech’s relationship with Poly-Med, a developer of biomaterial technologies, which it initially formalized in a June 2001 licensing agreement.

 

April 13, 2004

CANADIAN GENOMICS RESEARCHERS RECEIVE $123 MILLION TOWARDS PREDICTING, PREVENTING AND TREATING HUMAN DISEASE
Vancouver, April 13, 2004 – The Honourable Stephen Owen, Minister of Public Works and Government Services and Dr. Judith Hall, Vice-Chair of Genome Canada Board of Directors, today announced the approval of fourteen new large-scale applied-health genomics research projects totaling $123 million. Half of this funding will be provided by Genome Canada and half by other partners. One of the selected BC projects tackles a major and extremely alarming problem, adverse drug reactions in children. The five other projects involve managing cancer, diagnostic and therapeutic approaches to iron metabolism disorders, diagnosing and evaluating mental retardation, reducing transplant organ rejection, and personalizing treatment for victims of lung cancer.

April 13, 2004

International Wex Technologies Inc. Receives Regulatory Approval for an Open Label Clinical Trial
International Wex Technologies Inc. (Wex or the Company) is pleased to announce that it received regulatory approval (No Objection Letter) from Health Canada, on April 8, 2004, for initiating an Open-Label extension Clinical Trial for Tectin in patients with moderate to severe cancer-related pain. This multi-centre, safety and efficacy study is a long-term continuation of the current Pivotal Phase IIb/III trial that is underway and will be run in parallel.

 

April 13, 2004

Xenon Genetics Awarded $4.7 million in Funding from Genome Canada and Genome BC
Vancouver, Canada – Xenon Genetics announced today that it was awarded Cdn $4.7 million in funding from Genome Canada and Genome British Columbia to develop improved screening, diagnostic tests and therapeutic treatments for common iron metabolism disorders. Matching funds for the three-year project will be provided by Xenon.

 

April 13, 2004

Dragon Announces Update on the Letter of Intent to Merge with Oriental Wave Holding Ltd.
VANCOUVER, April 13 /CNW/ – Dragon Pharmaceutical Inc. (TSX: DDD, OTC BB:DRUG) (“Dragon”) today updates its previously announced Letter of Intent to merge with Oriental Wave Holding Limited (“Oriental Wave”).

 

April 8, 2004

Inflazyme to Acquire Adprotech Limited
VANCOUVER, B.C., CANADA and CAMBRIDGE, ENGLAND – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) and Adprotech Ltd., a private U.K. based company, today announced that they have entered into an agreement whereby, subject to necessary regulatory approvals, Inflazyme will acquire Adprotech. Inflazyme will issue approximately 12.7 million common shares to acquire all outstanding Adprotech shares in a deal valued at approximately CDN$20 million.

 

April 7, 2004

Neuro Discovery Inc. Announces 2003 Results and Successful Launch of First Fund
VANCOUVER, April 7 /CNW/ – Neuro Discovery Inc. (TSX Venture: “NDI”) is pleased to announce the audited financial and operating results of the year ended December 31, 2003. During the year, the Company successfully launched the Neuro Discovery Limited Partnership (“NDLP”), an institutional fund focused on promising neuroscience biotechnology companies.

April 7, 2004

CHRISTENSEN O’CONNOR JOHNSON KINDNESS PLLC ADDS ONE PATENT ATTORNEY AND TWO PATENT AGENTS
SEATTLE, Washington – Joy Y. Xiang, Timothy R. Wyckoff and Larry T. Harris have joined Christensen O’Connor Johnson KindnessPLLC, the Pacific Northwest’s leading intellectual property law firm.

 

April 5, 2004

AnorMED licenses cancer compound to NeoRx
AnorMED Inc. (TSX:AOM) today announced that it has licensed its platinum based anti-cancer agent, AMD473, to NeoRx Corporation (NASDAQ: NERX). Under the terms of the agreement, NeoRx was granted exclusive global rights, excluding Japan, to develop, manufacture and commercialize the drug candidate for treatment of any human disease. NeoRx plans to initiate clinical studies for AMD473 in one or more cancer indications in the second half of 2004.

 

April 5, 2004

Forbes Medi-Tech Announces European Phase II Trial Results for FM-VP4
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced preliminary results of the Phase II clinical trial of the Company’s cholesterol-lowering compound, FM-VP4, completed at the Academic Medical Centre in Amsterdam. The trial’s primary efficacy endpoint of significantly lowering low density lipoprotein (LDL) cholesterol was met. The reduction in LDL cholesterol, as compared to placebo, was 11%, with 33% of subjects at 400 mg per day achieving a greater than 15% reduction. Additionally, FM-VP4 continued to demonstrate an excellent safety profile with no difference between dosing and placebo groups.

 

April 1, 2004

International Wex Technologies Inc. receives a Screening Acceptance Letter from Health Canada
International Wex Technologies Inc. (the Company) is pleased to announce thatit has received a Screening Acceptance Letter from Health Canada regarding aCTA filing for an open-label extension study of Tectinâ„¢ in patients with moderate to severe cancer-related pain.

 

April 1, 2004

Xenon Genetics Discovers a Gene Linked to Peripheral Nerve Degeneration
Vancouver, Canada – A study published in the online edition of the American Journal of Human Genetics reports that researchers from Xenon Genetics have discovered a novel gene relating to peripheral neuropathy that results in an absence of sensations. This gene discovery adds further depth to Xenon’s neuroscience portfolio and could lead to novel therapeutic and diagnostic opportunities in patients with peripheral neuropathy.

 

March 31, 2004

Angiotech partner concludes enrollment in TAXUS V clinical trial
VANCOUVER, March 31 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI;TSX:ANP) today announced that its corporate partner, Boston ScientificCorporation, concluded enrollment in its TAXUS V de novo lesion clinicaltrial. Boston announced that it has enrolled 1,172 patients, surpassing therequired sample size of 1,108. The U.S. Food and Drug Administration (FDA) hasconfirmed that the Company has reached sufficient enrollment to meet all therequired trial analyses, and that it may therefore close enrollment in thetrial.

 

March 30, 2004

CHROMOS EXTENDS COLLABORATION AGREEMENT WITH LONZA BIOLOGICS PLC
Chromos Molecular Systems Inc. (“CHROMOS”; TSX: CHR) today announced that it has extended its collaboration agreement with Lonza Biologics PLC (“Lonza”) of Slough, England. This agreement provides Lonza researchers with non-exclusive access to Chromos’ ACE System for evaluation in its contract manufacturing business.

 

March 30, 2004

International Wex Technologies Inc. Announces Pain Management Portfolio Expanded – First Drug License Obtained in Canada
International Wex Technologies Inc. (the Company) is pleased to announce that Health Canada (Health Products and Food Branch) has issued Drug Identification Numbers (DIN) to the Company for topical CAPSAICIN CREAM. Drug Identification Numbers are assigned to prescription and over-the-counter drug products, and once issued, permits the manufacturer to market the drug in Canada. This important milestone marks the first product that the Company can sell in Canada, as authorized by government health officials.

 

March 29, 2004

International Wex Technologies Inc. Announces Peru Authorization
International Wex Technologies Inc. (the Company) is pleased to announce that through its subsidiary, Acro Pharm Corp. (formerly GlobalMed Corp.), and its distributor in Peru, a Sanitary Registry Authorization has been obtained for our product Tetrodoninâ„¢ (a product derived from our platform drug).

 

March 29, 2004

Cardiome initiates cardiac surgery clinical study, revises phase 3 guidance
Cardiome Pharma Corp (TSX: COM) today announced that it has commenced its second Phase 3 efficacy study of RSD1235 for the acute treatment of atrial fibrillation (AF). The study, called ACT 2, will evaluate the efficacy and safety of intravenous RSD1235 for the treatment of patients who have developed transient atrial fibrillation following cardiac surgery. ACT 2 is the second of an expected three Phase 3 clinical studies that Cardiome and its marketing partner Fujisawa Healthcare Inc. will undertake prior to filing for approval in the US.

 

March 29, 2004

QLT to Acquire Kinetek Pharmaceuticals Inc.
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it will be acquiring Kinetek Pharmaceuticals, Inc., a Vancouver-based privately-held biopharmaceutical company. The acquisition required the approval by special resolution of Kinetek shareholders, as well as that of the B.C. Supreme Court, both of which were obtained today.

 

March 26, 2004

Forbes Medi-Tech Signs Reducol(tm) Licensing and Distribution Agreement with Marco Hi-Tech
Vancouver, Canada. Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that it has signed a Licensing and distribution agreement for its cholesterol-lowering ingredient, Reducol(tm), with Marco Hi-Tech JV LLC of New York, N.Y. Under the terms of the co-exclusive four-year contract, Forbes will supply Reducol(tm) to Marco Hi-Tech for distribution to dietary supplement manufacturers. These manufacturers are expected to incorporate the ingredient into a variety of cholesterol-lowering supplements to be sold in natural health food stores across the United States.

 

March 25, 2004

International Wex Technologies Announces Change of Auditor
 

 

March 24, 2004

Dragon Announces a Proposed Merger with a Profitable, Fully-integrated Pharmaceutical Company
 

 

March 23, 2004

ANORMED SELLS GLOBAL PATENTS FOR FOSRENOL (LANTHANUM CARBONATE) TO SHIRE PHARMACEUTICALS GROUP
Vancouver, British Columbia – AnorMED Inc. (TSX:AOM) announced today that it has agreed to sell the global patents for FOSRENOL ® to Shire Pharmaceuticals Group plc, and one of its wholly owned subsidiaries, for up to US$31 million in milestone payments to be made upon regulatory approval in the United States, the European Union, and Japan.

 

March 22, 2004

MDX MEDICAL SELECTS ASCENTA FOR INVESTOR RELATIONS
For Immediate Release March 22, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX)MDX Medical announced today it has retained Ascenta Capital Partners Inc. to provide investor relations and financial communications services.

 

March 18, 2004

MDX MEDICAL ANNOUNCES BARRY ALLEN AS CHAIRMAN AND DIRECTOR
For Immediate Release March 18, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX)MDX Medical is pleased to announce that Mr. Barry Allen has joined the Company as Director and Chairman of the Board. In this role, Mr. Allen will assist MDX by providing leadership and strategic business expertise as the company develops and executes its business objectives.

 

March 18, 2004

INEX Releases 2003 Operating Results & 2004 Milestones
VANCOUVER, March 18 /CNW/ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) reported today its 2003 audited operating results. Highlights for the year included the commencement of a filing of a New Drug Application (NDA) seeking marketing approval from the US Food and Drug Administration (FDA) for its lead anticancer product Onco TCS. The Company completed filing the NDA on March 15, 2004 and announced on January 20, 2004 that it had entered into a strategic partnership with Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) to develop and commercialize Onco TCS in North America.

 

March 17, 2004

Angiotech licenses technology from The University of British Columbia
VANCOUVER, BC, March 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) today announced that it has licensed several novel technologies from The University of British Columbia (UBC) to further strengthen the Company’s portfolio of next-generation drug-loaded medical devices and biomaterials.

 

March 16, 2004

Angiotech Pharmaceuticals, Inc. announces results for the quarter and year ended December 31, 2003
VANCOUVER, March 16 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI;TSX:ANP) today reported financial results for the quarter and year endedDecember 31, 2003. Amounts, unless specified otherwise, are in Canadiandollars. At December 31, 2003, the exchange rate was approximately U.S. $1.00 to CDN $1.29.

March 16, 2004

QLT ANNOUNCES VISUDYNE(R) TO RECEIVE CENTERS FOR MEDICARE AND MEDICAID EXCEPTION ON ALLOWABLE REIMBURSEMENT LEVEL
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) and Novartis Ophthalmics, the eye health unit of Novartis Pharma AG (NYSE: NVS) announced today that the Centers for Medicare and Medicaid Services (CMS) has raised the Medicare allowable reimbursement rate for Visudyne ®. Effective April 1, 2004, the rate moves from approximately $1,304 to $1,404, as part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003–his rate was determined using the Average Selling Price for Visudyne in Q4 2003 + 6%.

March 16, 2004

TWINSTRAND THERAPEUTICS CLOSES SECOND TRANCHE IN $10M VENTURE FINANCING
Twinstrand Therapeutics, Inc., a private biopharmaceutical company, announces the recent closing of the second and final tranche of a $10 million venture capital financing.

 

March 15, 2004

INEX and Enzon Complete the Filing of a New Drug Application for Onco TCS
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) and Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) announced today that they have submitted the final section of a “rolling submission” of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA). The NDA is seeking marketing approval for Onco TCS as a single-agent treatment for patients with relapsed aggressive non-Hodgkin’s lymphoma

 

March 15, 2004

INTERNATIONAL WEX AND SABEX CONCLUDE AGREEMENT
International Wex Technologies Inc. (“Wex”) is pleased to announce the conclusion of a Manufacturing and Option Agreement with Sabex 2002 Inc. (“Sabex”). Under this agreement, Sabex will manufacture Wex’s clinical lots for Canada, the United States and worldwide.

 

March 15, 2004

EnGene Inc. Announces Eric A. Adams Joins as Chief Executive Officer and President
enGene, Inc. today announced that Eric A. Adams has joined the company as Chief Executive Officer (CEO) and President. He will also serve on the company’s Board of Directors. Mr. Adams brings more than 15 years of experience in pharmaceutical product development, commercialization and partnerships. Anthony T. Cheung, PhD., a co-founder of enGene who has served as President and CEO for the previous 3 years, will assume the role of Chief Scientific Officer (CSO). He will continue to be an active member of the Board.

March 15, 2004

ARC Pharmaceuticals Selected to Present at Invest Northwest 2004
VANCOUVER, March 15 /CNW/ – ARC Pharmaceuticals Inc. announced today that it has been selected to present at Invest Northwest, a life sciences and CEO investor conference, to be held March 22-23, 2004 at the Bell Harbor Conference Center in Seattle.

March 15, 2004

Cardiome Reports Year End Financials and Gives Outlook For 2004
Vancouver, Canada, March 15, 2004 – Cardiome Pharma Corp. (COM-TSX) (“Cardiome” or the “Company”) reported today financial results for the thirteen months ended December 31, 2003 (“Fiscal 2003”). The thirteen-month fiscal period is a result of the Company’s recent change of year-end from November 30 to December 31 to synchronize the fiscal reporting period with the majority of our industry peers.

 

March 11, 2004

NeuroMed Technologies Launches Phase I Clinical Trials for Chronic Pain Drug; Appoints New Board Member
VANCOUVER, March 11 /CNW/ – NeuroMed Technologies Inc., a Vancouver basedbiopharmaceutical company, today announced it has initiated Phase I clinicaltesting for its lead drug candidate for chronic pain, NMED-160, a calciumchannel blocker.

 

March 11, 2004

wex begins TRADing ON TORONTO STOCK EXCHANGE
International Wex Technologies Inc. (the “Company” or “Wex”) is pleased to announce that the Company’s common shares commenced trading today on the Toronto Stock Exchange. Wex has retained the trading symbol “WXI”. The company’s common shares no longer trade on the TSX Venture Exchange.

 

March 11, 2004

XILLIX APPOINTS DIRECTOR OF NORTH AMERICAN SALES
Richmond, B.C. – Xillix Technologies Corp. (TSX: XLX), a world leader in fluorescence endoscopy for the early detection of cancer, today announced the appointment of David Marsh as Director of North American Sales. Mr Marsh will be responsible for implementing the Company’s sales strategy across the United States and Canada.

March 11, 2004

XILLIX ANNOUNCES YEAR END 2003 RESULTS
Richmond, B.C. – Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced results for the year ended December 31, 2003.

March 9, 2004

TRADING ON THE TORONTO STOCK EXCHANGE COMMENCES
International Wex Technologies Inc. (the “Company” or “Wex”) is pleased to announce that the Company’s common shares will commence trading March 11, 2004 on the Toronto Stock Exchange. Wex will retain the trading symbol “WXI”. As of market close March 10, 2004, the Company’s common shares will no longer trade on the TSX Venture Exchange.

 

March 9, 2004

Cardiome Regulatory Filing Accepted for Review
Vancouver, Canada, March 9, 2004 – Cardiome Pharma Corp (TSX: COM) today announced that the United States Food and Drug Administration (FDA) has accepted for review Cardiome’s New Drug Application (NDA) for oxypurinol for the treatment of allopurinol-intolerant hyperuricemia (gout). Cardiome submitted the NDA application under the provisions of the Orphan Drug Act and under Subpart H of the Food and Drug Act in the U.S. on December 23, 2003. The FDA’s acceptance of the NDA for review does not represent any opinion of the FDA regarding the safety or efficacy of the product.

 

March 9, 2004

Aspreva Pharmaceuticals Completes First-Round Private Equity Financing, Raising $ US 57 million
Victoria, B.C., Canada; March 9, 2004 – Aspreva Pharmaceuticals Corporation, creators of a unique pharmaceutical asset partnering model, today announced the completion of a $57 million (Cdn$76 million) private equity financing.

 

March 8, 2004

Micrologix Completes $6.75 Million Offering
Vancouver, BC, CANADA, March 8, 2004 – Micrologix Biotech Inc. (TSX: MBI; OTC: MGIXF) announced today the issuance of 6.75 million units (“Unit”) at a price of $1.00 per Unit for gross proceeds of $6.75 million pursuant to the firm underwriting announced on February 19, 2004.

 

March 4, 2004

Angiotech Partner announces FDA approval for its TAXUS(TM) Express2(TM) paclitaxel-eluting coronary stent system
VANCOUVER, March 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) today announced that its corporate partner, Boston Scientific Corporation, has received approval from the U.S. Food and Drug Administration(FDA) to market its TAXUS(TM) Express2(TM) paclitaxel-eluting coronary stent system. Boston plans to launch the product in the United States immediately, and it has ample inventory in all sizes. The Company launched the TAXUS system in Europe and other international markets in February of 2003 and is the leader in those markets today.

March 2, 2004

Xillix Closes $15,750,000 Bought Deal Financing
Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that it has successfully closed its offering of 15,000,000 common shares at a price of $1.05 per share for total gross proceeds to Xillix of $15,750,000. The offering included 10,000,000 common shares sold to Sprott Securities Inc. and Dlouhy Merchant Group Inc., as co-lead underwriters, on a bought deal basis and an additional 5,000,000 common shares sold to the underwriters pursuant to the exercise of their option.

 

February 26, 2004

MDX MEDICAL ANNOUNCES MANUFACTURING OF ALPHA VERSIONS OF THE AVID PHANTOM
For Immediate Release February 26, 2004: Vancouver, Canada – MDX Medical Inc. (TSX.V: MDX)MDX Medical is pleased to announce that it has completed manufacturing of the Alpha units of the AVID “Universal” Phantom for use in verification of Intensity Modulated Radiation Therapy (IMRT) treatment plans. These two units will be sent to the BC Cancer Agency in Vancouver and the Nova Scotia Cancer Centre in Halifax for testing. Medical physicists at each site will conduct a variety of test procedures for confirmation of the Company’s product design specifications.

 

February 26, 2004

Abgenix Announces 2003 Fourth Quarter and Full Year Financial Results
FREMONT, Calif.–(BUSINESS WIRE)–Feb 24, 2004–Abgenix, Inc. (Nasdaq:ABGX) today reported financial results for the fourth quarter and full year ended December 31, 2003.

 

February 25, 2004

CONDITIONAL LISTING APPROVAL OF THE TORONTO STOCK EXCHANGE
International Wex Technologies Inc. (the “Company”) is pleased to announce that it has received conditional listing approval from the Toronto Stock Exchange (the “TSX”) for the listing of its common shares on the TSX. Listing on the TSX will be subject to the Company filing satisfactory final documentation with the TSX.

 

February 24, 2004

STRESSGEN REPORTS HSPE7 RESULTS FROM TWO CLINICAL TRIALS
San Diego, California USA – Stressgen announced today the results from two clinical trials for its lead compound, HspE7. The trials were designed to confirm previous results and primary endpoints for future Phase III pivotal trials. The Company reported that its Phase II trial for recurrent respiratory papillomatosis (RRP) showed high statistical significance in its primary endpoint of lengthening the interval between surgeries.

 

February 23, 2004

PCIS Launches the Biotech Roadmap
Vancouver – February 23, 2004 1:00 p.m. PST — PCIS (Pacific Coast Information Systems), a full service technology and consulting company, launched its Biotech Roadmap today at an event on the future of collaborations between IT and biotech. Alistair Duncan, CEO, Chromos Molecular Systems, Paul King, Director Life Sciences, PCIS, Barry Allen, President, VSM Medtech, and Francis Ouellette, Director, UBC Bioinformatics Centre were panelists at the event and each discussed how collaboration between IT and Biotechs can result in the implementation of the right technologies.

February 23, 2004

APPOINTMENT OF C.F.O. & VICE-PRESIDENT, CORPORATE COMMUNICATIONS
International Wex Technologies Inc. (the “Company”) is pleased to announce the appointment of Bruce Hay, CA, as Chief Financial Officer effective March 1, 2004 and the appointment of Don Evans as Vice President, Corporate Communications.

 

February 20, 2004

INFLAZYME ANNOUNCES COMPLETION OF ENROLLMENT IN ITS PHASE IIa ASTHMA STUDY
VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP), announced today that the enrollment of patients into the Phase IIa asthma study AVE0547/2001 with IPL512,602 has been completed. The study is being conducted by Aventis under the collaboration agreement between Inflazyme and Aventis.

 

February 19, 2004

Forbes Medi-Tech Increases Depth of its Medical & Scientific Advisory Board with Appointment of Four Key Leaders in Cardiovascular Research
Vancouver, Canada Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that further to the recent appointment of Dr. Eric Topol as Chairman of the Medical and Scientific Advisory Board the Company has added four leaders in Cardiovascular and Metabolic Syndrome research to Advisory Board. The new members are Steven E. Nissen, M.D., Daniel J. Rader, M.D., Thomas A. Pearson, M.D., M.P.H., Ph.D., and Dr. Steven Haffner, M.D. Forbes recently appointed Dr. Eric Topol from the Cleveland Clinic as Chairman of the Medical & Scientific Advisory Board and Scientific Consultant.

 

February 19, 2004

PHASE II CLINICAL TRIAL FOR TECTINâ„¢ APPROVED IN CHINA
International Wex Technologies Inc. (the “Company”) is pleased to announce that it has received approval from the State Food and Drug Administration (SFDA) of P.R. China to initiate the Phase II clinical trial for Tectinâ„¢ in late-stage cancer patients who are already receiving and are tolerant to opioid therapy for their underlying persistent and severe cancer pain.

 

February 19, 2004

MICROLOGIX ENTERS INTO FIRM UNDERWRITING FOR UP TO $7.5 MILLION OFFERING
Vancouver, BC, CANADA – February 19, 2004 – Micrologix Biotech Inc., a developer of anti-infective drugs (TSX: MBI; OTC: MGIXF), has entered into a firm underwriting with Canaccord Capital Corporation (“Canaccord”, “underwriter”) in which the underwriter has agreed to buy 5 million Units at a price of $1.00 per Unit, with an option to purchase up to 2.5 million additional Units for total gross proceeds of up to $7.5 million.

 

February 12, 2004

JAMES HOGGAN AND ASSOCIATES ADDS NEW ACCOUNT MANAGER
Vancouver, B.C. — James Hoggan and Associates Inc., one of Vancouver’s leading public relations and investor communications firms, is pleased to announce the appointment of John Kageorge as account manager.

 

February 11, 2004

MDX MEDICAL ANNOUNCES NEW ADDITIONS TO PRODUCT DEVELOPMENT TEAM
MDX Medical is pleased to announce the establishment of the Company’s Quality Assurance Team and an agreement with Drug and Device Development Co., Inc., Redmond, Washington, to serve as its Regulatory Affairs Consultant.

 

February 11, 2004

XILLIX ENTERS INTO AGREEMENT FOR A $10,500,000 BOUGHT DEAL
Richmond, B.C. Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that it has entered into a bought deal agreement with a syndicate of underwriters co-led by Sprott Securities Inc. and Dlouhy Merchant Group Inc. Under the agreement, the underwriters have agreed to purchase 10,000,000 common shares (“Common Shares) at a price of $1.05 per Common Share, resulting in gross proceeds to Xillix of $10,500,000. In addition, the underwriters have the option to increase the size of the offering by a further 5,000,000 Common Shares at the offering price by giving notice to Xillix prior to closing. The offering is expected to close on or about March 2, 2004. The transaction is subject to receipt of all necessary regulatory and stock exchange approvals.

 

February 11, 2004

ANORMED ANNOUNCES FISCAL 2004 THIRD QUARTER RESULTS
Vancouver, BC – AnorMED Inc. (TSX:AOM) today reported financial results for its third quarter ended December 31, 2003. AnorMED recorded a net loss of $ 4,359,000 ($0.17 per common share) in this quarter. This is lower than the net losses incurred in the third Fiscal quarter of 2003 of $5,305,000 ($0.21per common share) and comparable to the previous quarter ended September 30, 2003 of $4,049,000 ($0.16 per common share). Revenue for both the third quarter and first nine months of Fiscal 2004 is comprised mostly of interest income.

 

February 11, 2004

QLT REPORTS 2003 FOURTH QUARTER AND FULL YEAR EARNINGS PER SHARE OF $0.13 AND $0.65 AND PROVIDES GUIDANCE FOR 2004
VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today earnings per share, for the three months and full year ended December 31, 2003 were $0.13 and $0.65, respectively, in line with Company guidance for the full year. Unless specified otherwise all amounts are in US dollars and reported under US GAAP.

 

February 11, 2004

Response Biomedical Engages The Trout Group Leading New York-based Investor Relations Firm to Facilitate Exposure to US Capital Markets
VANCOUVER, Feb. 11 /CNW/ – Response Biomedical Corp. (RBM: TSX Venture Exchange), today announced that it has engaged The Trout Group LLC, a leading New York based investor relations firm, to facilitate the Company’s exposure to US capital markets by developing relationships with portfolio managers, investment bankers, industry analysts and the business news media. With extensive institutional investor relationships in the United States, Canada and Europe, The Trout Group provides strategic advisory and investor relations services to life science companies.

 

February 10, 2004

FDA APPROVES XILLIX’S REQUEST FOR EXPANDED CLINICAL TRIAL
Richmond, B.C. Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that the U.S. Food and Drug Administration (FDA) has approved Xillix’s request to expand the original Onco-LIFE (TM)„ · lung cancer clinical trial. This will allow the US clinical investigators to continue using Onco-LIFE and will give Xillix the option to include additional patient data in its Pre- Market Approval (PMA) Supplement submission if necessary.

 

February 9, 2004

Forbes Medi-Tech Completes Regulatory Filing Pursuant to Previous Financing
 

 

February 6, 2004

AnorMED Initiates Fourth Phase II Trial in Cancer Patients for AMD3100
Vancouver, British Columbia – AnorMED Inc. (TSX:AOM) announced today the initiation of its fourth Phase II clinical trial to evaluate AMD3100 as a new stem cell transplantation drug candidate for cancer patients. Clinical data to date in cancer patients shows AMD3100 effectively increases the number of stem cells available for transplantation. The strongest predictor of success in stem cell transplant is the number of stem cells available for transplantation.

 

February 5, 2004

Response Biomedical Joins Forces With General Dynamics To Pursue Global Biodefense Markets
VANCOUVER, Feb. 5 /CNW/ – Response Biomedical Corp. (RBM: TSX VentureExchange), has formed an alliance with General Dynamics Canada Ltd., abusiness unit of General Dynamics Corp. (GD: NYSE), aimed at integrating theResponse Biomedical RAMP System into General Dynamics Canada’s 4WARN System tomeet the real-time biological agent surveillance needs of the military andhomeland security agencies worldwide.

 

February 4, 2004

Boston Scientific announces start of enrollment in U.S.-based drug-eluting stent registry
VANCOUVER, Feb. 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI;TSX:ANP) today announced that its corporate partner Boston ScientificCorporation, has commenced enrollment in the ARRIVE registry program, whichplans to enroll 2000 patients at approximately 50 centers in the UnitedStates. It is designed to collect and analyze “real world” safety and clinicaloutcomes data for the TAXUS(TM) Express2(TM) paclitaxel-eluting stent systemin the treatment of patients with coronary artery disease. (A registry programenlists large numbers of clinicians to document the performance of a specifictherapy for a particular disease or condition.)

 

February 4, 2004

Response Biomedical Appoints Stan Yakatan to Board of Directors
Vancouver, British Columbia, February 4, 2004 – Response Biomedical Corp. (RBM: TSX Venture Exchange), is pleased to announce the appointment of Mr. Stan Yakatan, Chairman of US-based Katan Associates International, to the Company’s Board of Directors.

 

February 3, 2004

Forbes Medi-Tech Completes Dosing for Phase II clinical trial on FM-VP4
Vancouver, British Columbia — February 3, 2004 Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that dosing of subjects has been completed for the Phase II clinical trial of its novel cholesterol-lowering pharmaceutical, FM-VP4. The Phase II trial to measure the drug’s efficacy and safety is being conducted at the Academic Medical Center (AMC) in Amsterdam, one of the world’s leading centers for the management and research of dyslipidaemia.

 

February 3, 2004

Chromos and AviGenics sign licensing deal
BURNABY, BC and ATHENS, GA, Feb. 3 /CNW/ – Chromos Molecular Systems Inc.(“Chromos”; TSX: CHR) and AviGenics Inc. announced today that they have signeda license agreement under which AviGenics has acquired exclusive rights toChromos’ ACE System to generate transgenic avians for the development ofprotein therapeutics and other applications in the avian transgenic field.

 

February 3, 2004

Abgenix Begins Phase 1 Study of ABX-PTH in Patients with Secondary Hyperparathyroidism
FREMONT, Calif.–(BUSINESS WIRE)–Feb. 3, 2004–Abgenix, Inc. (Nasdaq:ABGX – News) announced today that the company has started a phase 1 clinical trial of ABX-PTH, a fully human monoclonal antibody generated by Abgenix’s technology platform that targets and neutralizes the action of parathyroid hormone (PTH).

 

February 3, 2004

Lifebank Distinguishes itself as Canada’s only Accredited Cord Blood Bank
Burnaby, B.C., February, 2004 – Lifebank Cryogenics Corp. (“Lifebank”) has received official notification by the American Association of Blood Banks (“AABB”) that is has satisfied all of the quality and operational systems assessment required to become Canada’s first and only AABB Accredited Cord Blood Stem Cell Bank.

 

February 3, 2004

Micrologix acquires clinical-stage hepatitis C drug candidate
Micrologix Biotech Inc., a developer of anti-infective drugs (TSX: MBI – News; OTC: MGIXF – News), has acquired the global rights to celgosivir (to be designated as “MBI-3253”), a Phase I/II clinical-stage compound, from Virogen Ltd. (UK). Celgosivir, which has been in over 600 subjects in human clinical studies to date, is a novel, oral antiviral agent under development for the treatment of chronic hepatitis C virus (HCV) infections. Micrologix intends to initiate Phase II clinical development with celgosivir in calendar 2004.

February 2, 2004

 

MDX MEDICAL ANNOUNCES BELOUD MANAGEMENT CONSULTANTS LTD. AS MARKET-MAKER
MDX Medical Inc. is pleased to announce that it has retained Beloud Management Consultants Ltd. of Kelowna, B.C., to provide market-making services.

 

January 30, 2004

Angiotech Pharmaceuticals to participate in Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
VANCOUVER, Jan. 30 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), is scheduled to participate in the 2004 Merrill Lynch GlobalPharmaceutical, Biotechnology & Medical Device Conference hosted by MerrillLynch.

 

January 30, 2004

ABGENIX TO RECEIVE MILESTONE PAYMENT FROM PFIZER FOR THIRD IND FROM ONGOING COLLABORATION
FREMONT, Calif., January 30, 2004 – Abgenix, Inc. (Nasdaq: ABGX) announced today that it will receive a milestone payment from Pfizer (NYSE: PFE), triggered by Pfizer’s recent filing of an Investigational New Drug (IND) application with the FDA.

 

January 30, 2004

MDX MEDICAL CLOSES $1 MILLION OFFERING
MDX Medical Inc. (the “Company”) is pleased to announce that it has closed the public offering (the “Offering”) announced on December 10, 2003, raising gross proceeds of $1,000,000.20 through the sale of units at $0.30 per unit by way of a Short Form Offering Document (the “Offering Document”) in accordance with TSX Venture Exchange Policy 4.6 and a concurrent private placement to accredited investors (the “Private Placement”).

 

January 30, 2004

Final Closing of $10,000,000 Financing Including a Fully Subscribed Overallotment of $4,000,000
International Wex Technologies Inc. (the “Company”) today announced that it has closed a private placement of an additional 1,200,000 units at a price of $5.00 per unit raising gross proceeds of $6,000,000. The private placement was originally announced on December 11, 2003 and was led by Jennings Capital Inc, as agent.

 

January 30, 2004

XILLIX SUBMITS REQUEST FOR EXPANDED CLINICAL TRIAL TO FDA
Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today announced that it has submitted a request to the U.S. Food and Drug Administration (FDA) to expand the original Onco- LIFE(TM) lung cancer clinical trial.

 

January 29, 2004

QLT AND NOVARTIS ANNOUNCE CENTERS FOR MEDICARE & MEDICAID SERVICES INTEND TO REIMBURSE VISUDYNE(R) FOR OCCULT AND MINIMALLY CLASSIC LESIONS IN AMD
VANCOUVER, CANADA and EAST HANOVER, NEW JERSEY–QLT Inc. (NASDAQ: QLTI; TSX: QLT) and Novartis Pharma AG, Ophthalmics, the eye health unit of Novartis AG (NYSE: NVS), announced that the Centers for Medicare & Medicaid Services (CMS) has determined that the evidence supports reimbursement for patients treated with Visudyne(R) for age-related macular degeneration (AMD) with occult and minimally classic lesions that are four disc areas or less in size and have evidence of recent disease progression. Medicare already offers coverage for Ocular Photodynamic Therapy (OPT) in AMD with predominantly classic lesions.

 

January 29, 2004

Boston Scientific announces French reimbursement for TAXUS(TM) Express(2)(TM) paclitaxel-eluting stent system
VANCOUVER, Jan. 29 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI; TSX:ANP) announced today that its corporate partner Boston Scientific Corporation, has received reimbursement approval from the French government for its TAXUS(TM) Express(2)(TM) paclitaxel-eluting coronary stent system. This approval will enable patients to be treated with the TAXUS stent system in private clinics and hospitals. TAXUS was previously available in France primarily through public hospitals. The Company said the product is available for immediate shipment to private facilities.

 

January 29, 2004

Lifebank Cryogenics Corp. Quarterly Financial Report for the quarter ended November 30, 2003.
 

 

January 28, 2004

CHRISTENSEN O’CONNOR JOHNSON KINDNESS PLLC ANNOUNCES NEW MEMBERS
SEATTLE, Washington – Barry F. McGurl, Shoko I. Leek, Mauricio A. Uribe and W. David Shenk have been promoted to members at CHRISTENSEN O’CONNOR JOHNSON KINDNESSPLLC, the Northwest’s leading intellectual property law firm.

 

January 27, 2004

XILLIX PROVIDES UPDATE ON REQUEST FOR CONTINUED ACCESS AND PMA SUPPLEMENT SUBMISSION
Richmond, B.C. Xillix Technologies Corp. (TSX:XLX), a world leader in fluorescence endoscopy, today confirmed that it believes that the U.S. Food and Drug Administration (FDA) review of its Request for Continued Access is progressing favorably. The Company has also requested a meeting with the FDA to consider converting its Request for Continued Access into a request for expansion of the original Onco-LIFE (TM) clinical trial approved by the FDA.

 

January 26, 2004

Lifebank Announces Strategic Relationship with One of the Largest Obstetrical Groups in Ottawa
 

 

January 23, 2004

QLT Announces Effectiveness Of Its Registration Statement On Form S-3 For Its August 2003 Private Placement Of Convertible Notes
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that its Registration Statement on Form S-3, with respect to the resale of its $172,500,000 aggregate principal amount 3.0% Convertible Senior Notes (“Notes”) due 2023 and the common shares issuable thereunder, was declared effective on Friday, January 23, 2004, by the U.S. Securities and Exchange Commission. QLT will not receive any proceeds from the resale of the Notes and underlying common shares.

 

January 22, 2004

QLT Announces Visudyne(R) Sales For Fourth Quarter
VANCOUVER, CANADA–QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne(R) (verteporfin) sales of approximately US$95.9 million for the quarter and US$357 million for the year ended December 31, 2003. Visudyne sales for the fourth quarter and the full year represent increases of 24% and 24% over sales in the fourth quarter and annual sales in 2002 respectively.

 

January 22, 2004

Inex Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will present at the Piper Jaffray Healthcare Conference at The Pierre Hotel in New York, New York on Tuesday, January 27, 2004 at 3:30 PM EST. David Main, INEX’s President and CEO, will give a 25-minute presentation providing an update on the Company. The presentation will be webcast and can be accessed through the INEX website at www.inexpharm.com for up to 30 days after the presentation.

 

January 21, 2004

Angiotech shareholders approve stock split and stock option plan at special meeting
VANCOUVER, Jan. 21 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI;TSX:ANP) today announced that shareholders of the Company approved all matters at its special shareholders meeting including a two-for-one stock split and a new stock option plan.

 

January 21, 2004

MICROLOGIX MEETS WITH FDA ON MBI-226
Vancouver, BC, CANADA – January 21, 2004 – Micrologix Biotech Inc., a developer of anti-infective drugs (TSX: MBI; OTC: MGIXF), has met with the United States Food & Drug Administration (“FDA”) to address the regulatory requirements for a New Drug Application (NDA) for MBI-226, a topical cationic peptide currently in Phase III development for the prevention of catheter-related bloodstream infections. In summary, an NDA path forward for MBI-226 can be achieved without the requirement for a statistically significant reduction in catheter-related bloodstream infections as a primary endpoint. The NDA requirements for MBI-226, which may include a confirmatory second Phase III study, will be established in consultation with an FDA representative over the next several months, using the secondary endpoints from a first Phase III study completed in July 2003 as a basis for seeking approval.

 

January 20, 2004

Enzon and INEX Sign Commercialization Partnership for Oncology Drug Onco TCS
Bridgewater, NJ, and Vancouver, CanadaEnzon Pharmaceuticals, Inc. (“Enzon”; NASDAQ: ENZN) and Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) today announced a strategic partnership to develop and commercialize INEX’s proprietary oncology product Onco TCS.

 

January 20, 2004

ABGENIX ANNOUNCES ABX-EGF ENTERS PIVOTAL TRIAL
FREMONT, Calif., Jan. 20, 2004 – Abgenix, Inc. (Nasdaq: ABGX) today announced that its partner, Amgen, is beginning a pivotal trial for its fully human monoclonal antibody, ABX-EGF, as a third-line monotherapy in colorectal cancer patients, with enrollment expected to begin shortly.

 

January 20, 2004

INEX Makes Milestone Payment to Former Partner
VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that the strategic partnership it has signed with Enzon Pharmaceuticals, Inc. (“Enzon”; NASDAQ: ENZN) to commercialize its proprietary oncology product Onco TCS has triggered the Company’s obligation to make a US$3 million cash payment to its former joint venture partner, Elan Corporation, plc (“Elan”; NYSE: ELN).

 

January 20, 2004

Angiotech Pharmaceuticals to participate in US Bancorp Piper Jaffray Health Care Conference
VANCOUVER, Jan. 20 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the US Bancorp Piper Jaffray Health Care Conference hosted by US Bancorp Piper Jaffray.

 

January 19, 2004

QLT Announces Discount to Physician Customers in Response to the Reduction in Medicare Reimbursement for Visudyne(R)
VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today a temporary discount to physician customers that will allow the purchase of Visudyne(R) at a reduced cost of $1,295, down from the current price of $1,350. This decision was made in response to the reduction in reimbursement for Visudyne by Medicare on January 1, 2004, as part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

 

January 14, 2004

Xenon Genetics Selects Clinical Candidates for its Metabolic Syndrome Program
VANCOUVER, Jan. 14 /CNW/ – Xenon Genetics today announced significantadvances in its lead Metabolic Syndrome (SCD1) Program. The Company hasselected clinical candidates for formal pre-clinical development, achieved invivo efficacy in multiple clinically relevant animal models and expects toadvance into the clinic within approximately twelve months.

 

January 14, 2004

Response Biomedical Generates 2003 Revenue of $1.4 Million
Vancouver, BC, January 14, 2004–Response Biomedical Corp. has reported revenue for the year ended December 31, 2003 of $1.4 million (unaudited), compared with $190,000 in 2002. Since January, 2003, the Company has sold more than 125 RAMP Systems. During the fourth quarter, the Company generated approximately $420,000 exclusively from product sales, and recorded revenue of $196,000 in December. The Company also began experiencing repeat orders for high margin biodefense test cartridges beginning in November, and West Nile Virus test sales are materializing ahead of schedule.

 

January 13, 2004

Genome British Columbia Attracts Renowned Researcher From USA as Chief Scientific Officer
Vancouver, B.C. – Monday, January 12, 2004: Dr. Alan Winter, President and CEO of Genome British Columbia announces the appointment of Dr. Donald Riddle as Chief Scientific Officer for Genome British Columbia.

 

January 13, 2004

AnorMED Expands FOSRENOL ® Licensing Agreement With Shire Pharmaceuticals Group plc
Vancouver, BC – January 13, 2004 – AnorMED Inc announced today that it has expanded the terms of its licensing agreement with Shire Pharmaceuticals Group plc for lanthanum carbonate (FOSRENOL ®). The terms of the new license grant Shire exclusive rights to develop, manufacture, use and sell FOSRENOL worldwide for all potential human indications and veterinary uses.

 

January 9, 2004

Active Pass Pharmaceuticals, Inc. Announces Promotion of David MacDonald to President & Chief Operating Officer
Vancouver, BC – January 9, 2004 – Active Pass announces the promotion of Dr. David MacDonald to the position of President & Chief Operating Officer. Concomitant with the appointment, Dr. MacDonald joins the Company’s Board of Directors. Commenting on the appointment, Chief Executive Officer Dr. Peter B. Reiner stated, “It is a rare privilege to have someone of David’s talents within the organization. His contributions to the business have been exemplary, and we are delighted to have him take on these additional responsibilities as the Company continues its transition from discovery to development.”

 

January 6, 2004

Chemokine Therapeutics Corp. Files Orphan Drug Application with FDA for CTCE-9908, a Novel Chemokine Targeted Agent for the Treatment of Osteosarcoma
Lake Forest, CA and Vancouver, BC — January 02, 2004 – Chemokine Therapeutics Corp. announced today that it has filed an application with the FDA for an orphan drug designation of its novel chemokine targeted agent, CTCE-9908 for the treatment of osteosarcoma.